The role of new ultrasound modalities to refine the diagnostic workup on women with cervical carcinoma by Pálsdóttir, Kolbrún
From Department of Women’s and Children’s health
Karolinska Institutet, Stockholm, Sweden
THE ROLE OF NEW ULTRASOUND 
MODALITIES TO REFINE THE  
DIAGNOSTIC WORKUP ON WOMEN WITH 
CERVICAL CARCINOMA
Kolbrún Pálsdóttir
Stockholm 2019
All previously published papers were reproduced with permission from the publisher.
Published by Karolinska Institutet
Layout: Árni Torfason
Printed by Eprint AB
© Kolbrún Pálsdóttir, 2019
ISBN 978-91-7831-486-7
The role of new ultrasound modalities to 
refine the diagnostic workup on women  
with cervical carcinoma
THESIS FOR DOCTORAL DEGREE (Ph.D.)
Publicly defended in Rolf Luft Auditorium L1, Karolinska University Hospital, Solna
Friday June 14th 2019 at 9:00 am
By
Kolbrún Pálsdóttir 
Principal Supervisor:
Associate professor Elisabeth Epstein 
Karolinska Institutet
Department of Clinical Science and Education
Division of Södersjukhuset
Co-supervisor(s):
Professor Lennart Blomqvist 
Karolinska Institutet
Department of Molecular Medicine and 
Surgery
Division of Diagnostic Radiology
Professor Ole Mogensen
Aarhus University and University Hospital
Department of Gynaecology and Obstetrics,
Division of Gynaecological Cancer Surgery
Opponent:
Associate professor Andreas Günthert
University of Bern, Switzerland
Department of Obstetrics and Gynecology
Examination Board:
Associate professor Hanna Dahlstrand
Karolinska Institutet
Department of Oncology-Pathology and
Uppsala University
Department of Immunology, Genetics and 
Pathology
Associate professor Karin Stålberg
Uppsala University
Department of Women’s and Children’s 
health
Division of Obstetrics and Gynecology
Associate professor Torkel Brismar
Karolinska Institutet
Department of Clinical Science, Intervention 
and Technology (CLINITEC)
Division of Radiology

To my parents 
Mamma og pabbi þessi bók er tileinkuð ykkur
Menntun er máttur

Abstract
Background: Cervical cancer is the fourth most common female cancer in the world and has tradi-
tionally been clinically staged not including imaging. Despite that, clinicians depend on diagnostic 
imaging in the management of patients to triage them to treatment. Ultrasonography (US) is the 
most widely used diagnostic imaging technique by gynecologists worldwide and is equally accurate 
as Magnetic resonance imaging (MRI) for local assessment of cervical cancer in the pelvis in low 
volume disease, whereas both methods lack accuracy for detection of lymph node metastasis. New 
ultrasound modalities such as three-dimensional ultrasonography (3D US), contrast-enhanced ultra-
sonography (CEUS) and strain elastography (SE) have shown promising results in the assessment 
of tumours, but the clinical value in cervical cancer patients is uncertain. The aims of this thesis 
were to explore the clinical value of 3D US, CEUS and SE and to assess the inter-rater agreement of 
conventional US and MRI in the assessment of patients with cervical cancer.
Methods: Study I was a multicenter study including 104 women with surgically resectable cer-
vical cancer from 5 European institutions. Studies II-IV were based on a single center cohort of 93 
women with all stages of cervical cancer, from Karolinska University Hospital. In study I subjective 
evaluation was compared to objective measurements of 2D and 3D US parameters for prediction of 
deep stromal and parametrial invasion as well as lymph node metastases. In study II semi-quantita-
tive parameters and filling pattern of CEUS were compared in 49 patients with cervical cancer and 
21 healthy controls. The features of SE in 30 patients with all stages of cervical cancer were explored 
in study III. In study IV the inter-rater agreement of raters with varying experience on US and MRI 
were compared in off-line settings for the assessment of cervical tumours in a cohort of 60 patients 
with all stages of cervical cancer.
Results: Subjective assessment with 2D US had high accuracy to detect deep stromal and para-
metrial invasion (sensitivity 91% and 100%; specificity 97% and 95% respectively) but not to predict 
lymph node metastases. Tumour size measured by 2D and volume measured by 3D US were accurate 
to predict deep stromal invasion (AUC 0.83 and 0.85) but outperformed by subjective assessment. 3D 
vascular indices (VI, VFI, FI) had no value to predict deep stromal invasion or lymph node metastases. 
A focal CEUS pattern had a higher specificity 91% versus 73% (p=0.62) and a similar sensitivity 80% 
versus 85% (p=1.00) compared to subjective assessment using conventional US for tumour detec-
tion. The semi-quantitative CEUS parameter area under the time intensity curve had high accuracy 
to separate tumour lesions from healthy stroma (AUC 0.923, p<0.001). Size measures of early stage 
tumours were accurate with SE (mean difference -0.11 mm, p=0.66) with no bias found. An elasticity 
score of 4-5 was found in 45% (9/20) with early stage and 80% (8/10) with advanced disease where 
SE was even useful in 7/10 (70%) of cases to delineate tumour borders. The inter-rater agreement for 
tumour visualization, 1/3 deep stromal and parametrial invasion was moderate for US raters (0.4-0.6) 
and moderate-good (0.4-0.8) for MRI raters irrespective of experience. 
Conclusion: Subjective 2D US assessment is accurate for detecting deep stromal and parametrial 
invasion where it outperforms objective measurements with 2D and 3D vascular indices. A focal 
contrast pattern with CEUS has high specificity and high accuracy for tumour detection. SE is accu-
rate to measure tumour size and may improve delineation of advanced tumours. In off-line settings, 
inter-rater agreement is moderate for US raters and moderate-good for MRI raters irrespective of 
experience.
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Figure 1. The estimated age-standardized incidence rates for cervical cancer globally in 2018. Data 
source: GLOBOCAN 2018, Graph production: IARC (http://gco.iarc.fr/today) World Health Organi-
zation.
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1 Introduction
Ultrasonography (US) is the most widely used diagnostic modality in gynecology 
worldwide. Studies have verified a high accuracy of the method for evaluation of 
patients with low volume cervical cancer (1) while new modalities such as three-di-
mensional ultrasonography (3D US), contrast enhanced ultrasound (CEUS) and 
strain elastography (SE) are less studied.
In a global perspective cervical cancer is a major burden as the fourth most com-
mon cancer among females (2) (Figure 1). As a result of successful prevention with 
nationwide screening programs and since recently vaccination, cervical cancer is 
now relatively uncommon in the Nordic countries (3). Due to lacking resources 
where cervical cancer has the highest incidence, the disease has been staged 
clinically according to The International Federation of Obstetrics and Gynecology 
(FIGO). Studies have reported the clinical system as insufficient, both in terms of 
low accuracy and by ignoring disease status of the pelvic lymph nodes, an import-
ant prognostic factor. Recently a new staging system was introduced (4) allowing 
findings from imaging such as Magnetic Resonance Imaging (MRI) and US to deter-
mine disease stage. MRI has since 15 years been included in the management of 
patients with cervical cancer in high-income countries both for diagnostic workup 
as well as treatment planning. The limitations are in the diagnostic workup of small 
tumours < 10 mm, the low sensitivity for detection of lymph node metastasis and 
restricted access in many areas in the world (5). As an inexpensive, widely available 
and accurate method, ultrasonography is an important alternative and complement 
to MRI even if the limitations are the same regarding assessment of lymph nodes. 
To be able to further refine the diagnostic accuracy for local tumour assessment and 
lymph node status new methods are required.
This thesis focuses on the value of new ultrasound techniques as a complement 
to conventional US in the assessment of patients with cervical cancer as well as the 
reliability of US in comparison to MRI in this patient group.
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2 Background
2.1 ANATOMY
The uterine cervix is the most caudal part of the female uterus, marking the bor-
ders between uterus and the vagina. It is derived from the Müllerian ducts bilat-
eral in the embryo that by fusion in the midline form the fallopian tubes, uterus, 
the uterine cervix, the upper third of the vagina as well as the tissue surrounding 
these organs (6). The uterine cervix is composed of 90% fibrotic stromal tissue and 
10% smooth muscle surrounding the fibrous stroma more superficially, connecting 
the cervix with the vaginal wall. The connective tissue lateral to the uterine cervix, 
including mainly lymphatic tissue and vessels to the uterus and vagina is in surgical 
terms called the lateral parametrium but anatomically the cardinal ligament. The 
dorsal part connecting the uterine cervix to the sacrum are the bilateral uterosa-
cral ligaments, that form the posterior parametrium and mark the lateral borders 
on both sides for the rectovaginal space (7) (Figure 2). In front of the cervix lies 
the urinary bladder in close adjunction covering the isthmus of the uterus and the 
anterior cervix. Where the ureters enter the bladder anterolaterally on both sides 
is called the ventral or anterior parametrium. In collective terms all the the tissue 
surrounding the cervix is named pericervical tissue.
Figure 2a. Anatomy of the inner female genitalia. Figure: Caroline Castoriano Gade
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The vaginal part of the uterine cervix is covered by the same squamous epithe-
lium as rest of the vagina. The vaginal wall and cervix meet circumferentially about 
1,5 or 2 cm from the most caudal part of the cervix forming the vaginal fornices. The 
endocervical canal leading to the uterine cavity is covered by columnar epithelium. 
These two different layers meet at the junctional zone at the external os which is 
variably exposed in relation to hormonal changes and age. At this fusion site the 
epithelium is most vulnerable and for that reason the majority of cervical cancer 
lesion grow from there. The most usual growth pattern for cervical tumours is 
through the cervical stroma and into the parametrium laterally, ventrally or dorsally 
furthermore to lymph nodes in the pelvic or paraaortic region. In the more exofytic 
growing lesions the tumours tend to disseminate onto the vaginal wall and fornices. 
2.2 EPIDEMIOLOGY
Cervical cancer is the fourth most common malignancy among females worldwide, 
with the largest proportion of women affected in low and middle income coun-
tries (2) (Figure 1). In Sweden and other western countries it is less common as the 
third most common gynecological malignancy after endometrial cancer and ovarian 
Backside
Internal os
Uterosacral
ligament
Endocervical
canal
External os
Cervical stroma
Lateral
Parametrium
Uterine artery
Front view
Figure 2b. Uterine cervix with surrounding structures. Figure: Caroline Castoriano Gade.
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cancer (8). However, the yearly incidence has increased since 2014 with a peak of 
575 new cases in the year 2015. Standardized for age the yearly incidence is from 
6.6-8.8/100.000 which is comparable to rest of the Nordic countries (9) (Figure 3). 
The incidence is highest in women in the forties when 1/3 of all cases are diagnosed 
and in women around 70 years, with a median age 48 years at diagnosis. Prognosis 
is strongly related to the dissemination of disease at the time of diagnosis with five 
years overall survival (OS) > 90% for patients diagnosed in stage I with negative 
pelvic lymph nodes (10).
2.3 RISK FACTORS AND PREVENTION
2.3.1 HPV infection
The precursor of the disease; cervical intraepithelial neoplasia (CIN, dysplasia) is 
without symptoms and is caused by a sexually transmitted infection by human pap-
illoma virus (HPV). There are hundreds of different HPV strains where some have 
been strongly associated with the risk of developing cervical cancer (11). Those 
together are called high-risk strains or HRHPV. The most common high risk types are 
Figure 3. Age standardized incidence (red line) and mortality (blue) of cervical cancer in the Nordic 
countries and age standardized incidence (green) and mortality (yellow) in Sweden. Statistics and 
figure from NORDCAN(3).
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16 and 18 that together are found in about 70% of all cervical cancers (11). Other 
strains include 31, 33, 45, 58 and many more as at least fifteen different high-risk 
types have been identified (12). HRHPV is found in all cervix cancer lesions (13) and 
is a necessary but not a sufficient trigger alone to cause the disease. Over 90% of 
women who get infected do not develop cervical cancer but heal from the infection 
spontaneously within two years (14). However in those with persistent infection 
especially type 16 the risk of developing high-grade dysplasia or cancer is increased 
with up to 22% (15). 
2.3.2 Other risk factors
It is not fully understood why some women develop chronic HPV infection and 
thereby have increased risk of developing cancer. Some co-factors associated with 
increased risk for cervical cancer have been identified such as: long term use of 
oral-contraceptive especially in combination with smoking, high number of live 
births, smoking and increasing number of sex partners (16-18). Immunologically 
deprived individuals such as HIV positive or transplanted women have a higher 
risk of persistent HPV infection, high grade CIN and invasive cervical cancer due to 
impaired cell-mediated immunity (19, 20). 
2.3.3 Prevention
Since the 1960s there is a screening program that through nationwide coverage 
reaches to women in all regions in Sweden (21). Through the years the method 
has evolved from Papanicolaou (Pap) smear on microscopic glass into today’s liq-
uid based cytology tests with possibilities to simultaneously test for high-risk HPV 
types. According to the newly updated national guidelines for cervical cancer pre-
vention by the National board of Health and Welfare in Sweden (Socialstyrelsen), 
the recommended age of women for screening is 23–64 years with liquid-based 
cytology, including HPV testing for women older than 30 years with recommended 
interval for testing 3 years for age group 23-49 and seven years for women 50 years 
and older (22). The inclusion of HPV testing in to the screening program is based 
on the results from 4 large European randomized controlled trials showing a 60% 
higher protection against cervical carcinoma with HPV screening compared to tra-
ditional cytology as the HPV testing targets the high risk population (23). In cases 
of high grade CIN or persistent low-grade dysplasia with HRHPV the recommended 
treatment is destruction of the junction zone / epithelium of the cervix usually by 
cone biopsy of the uterine cervix. In that way most infections are effectively cured 
with minimized risk for cancer later in life (24). 
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2.3.4 Vaccination
Introduction of bivalent, quadrivalent and the new ninevalent HPV vaccine is 
expected to decrease the incidence of cervical cancer. All the vaccines are effective 
against the most common types 16 and 18, the quadrivalent type further protects 
against type 6 and 11 just as the ninevalent vaccine that in addition protects against 
types 31, 33, 45, 52 and 58 (25-27). Papers have already emerged reporting long-
term effectiveness, decreased incidence of CIN, Adenocarcinoma in situ (AIS) and 
persistent infection by high-risk subtypes of HPV mostly 16 and 18 in vaccinated 
populations (28-30). A nationwide vaccination program for girls 10-12 years old 
started 2012 in Sweden, aiming for vaccination before sexual debut. This is expected 
to reverse the negative trend seen during the last years with increasing incidence 
of cervical cancer although it will take at least a decade before the effect becomes 
prominent.
2.4 HISTOLOGY
The most common histology type is squamous cell carcinoma accounting for 
75-80% of cases (31, 32). Adenocarcinoma is diagnosed in about 20% of cases as 
the second most common type. Other types like mixed adenosquamous type, clear 
cell carcinoma and neuroendocrine small cell cancer are less common but more 
aggressive with worse prognosis, especially the neuroendocrine small cell type that 
often presents with distant metastases at the time of diagnosis (33). In the last 
decades the incidence of adenocarcinoma has been increasing at the same time as 
the incidence of squamous cell carcinoma has decreased (8). This indicates lacking 
efficacy of the screening program finding the precursors of adenocarcinoma. 
2.5 CLINICAL SIGNS AND STAGING 
With an established invasive lesion of cervical cancer, the main symptoms are: vag-
inal bleeding after intercourse, pelvic pain and abnormal vaginal discharge. Some 
women with cervical cancer present late and without symptoms, especially with 
adenocarcinoma growing in the cervical canal where the lesion is not always visual-
ized by vaginal examination (Figure 4). Usually the tumour is seen macroscopically 
where further histology is verified by a tissue biopsy. Other tumours are diagnosed 
at early stages by cone biopsy, performed as a result of dysplasia found with routine 
screening. In Swedish population, approximately 30% of all cervical cancer is found 
by screening especially in younger patients (34-36).
Traditionally cervical tumours have been staged according to the International 
Federation of Obstetrics and Gynecology (FIGO) clinical staging criteria, (Table 1) 
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(37). It includes gynecological examination under anesthesia with palpation of the 
pelvis, cystoscopy, rectoscopy and if needed X-ray of the lungs. No obligatory imag-
ing was included but according to the revised FIGO criteria from 2009, usage of 
imaging modalities such as magnetic resonance imaging (MRI) was encouraged (37). 
The reason for excluding advanced imaging has been the lack of available imaging 
modalities in countries with limited resources where cervical cancer is common. 
Studies have found the clinical classification system underestimating the disease 
stage both the early stage 15-30% and the more advanced stages up to 40% at stage 
IIIB as compared to surgical staging (38-40) as well as not taking into consideration 
the metastatic status of lymph nodes. A moderate inter-observer agreement for 
clinical staging in the hands of experienced examiners has been reported (41). For 
this reason and because of the clinical significance of lymph node metastases a new 
staging system was introduced by FIGO 2018 that includes imaging and pathology 
in addition to clinical findings to decide disease stage, thereby incorporating a new 
stage IIIC (lymph node metastases) into the staging system (Table 1). Furthermore 
lateral extension of the microscopic lesions IA has been eliminated and by adding 
IB3 for tumours > 4 cm the former stage IB1 becomes IB2. It is recommended that 
when in doubt the lower staging should be assigned (4). For clarification in this 
thesis, FIGO classification system from 2009 is applied unless otherwise specified.
Uterus Adnexa
Lateral 
parametrium
Vaginal mucosa Tumour in the endocervical canal
Mucosa on the external os
Figure 4. A specimen from radical surgery, a) Showing from above down: Uterus with adnexa, 
lateral parametrium and vaginal mucosa. B) uterus and uterine cervix; Arrows pointing at tumour in 
the endocervical cancal, covered by mucosa on the external cervical os. The tumour was difficult to 
visualise macroscopically by gynecological examination. 
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2018	 2009	 Definition
I I The carcinoma is strictly confined to the cervix (extension to the uterine corpus 
should be disregarded)
 IA Invasive cancer identified only microscopically (All gross lesions even with superfi-
cial invasion are Stage IB cancers) Invasion is limited to measured stromal invasion 
with a maximum depth of 5 mm and no wider than 7 mm.
IA  For FIGO 2018 only maximum depth of invasion ≤ 5 mm 
IA1 IA1 Measured invasion of stroma ≤ 3 mm in depth (and ≤ 7 mm width)
IA2 IA2 Measured invasion of stroma > 3mm and < 5 mm in depth (and ≤ 7 mm width)
 IB Clinical lesions no greater than 4 cm in size
IB  Invasive carcinoma with measured deepest invasion ≥ 5 mm (greater than IA)
 IB1 Clinical lesions no greater than 4 cm in size
IB1   Invasive carcinoma ≥ 5 mm depth of stromal invasion, and < 2 cm in greatest 
dimension
 IB2 Clinical lesions > 4 cm in size
IB2   Invasive carcinoma ≥2 cm and <4 cm in greatest dimension
IB3  Invasive carcinoma ≥4 cm in greatest dimension
II II The carcinoma extends beyond the uterus, but has not extended onto the pelvic 
wall or the lower third of vagina 
IIA IIA Involvement of up to the upper 2/3 of the vagina. No obvious parametrial involve-
ment
IIA1 IIA1 Invasive carcinoma <4 cm in greatest dimension
IIA2 IIA2 Invasive carcinoma ≥4 cm in greatest dimension
IIB IIB (Obvious) parametrial involvement but not onto the pelvic sidewall
III III The carcinoma has extended onto the pelvic sidewall. On rectal examination there 
is no cancer free space between the tumour and pelvic sidewall. The tumour 
involves the lower third of the vagina. All cases of hydronephrosis/nonfunctioning 
kidney should be included unless they are known to be due to other causes
IIIA IIIA Involvement of the lower vagina but no extension onto the pelvic sidewall
IIIB IIIB Extension onto the pelvic sidewall, or hydronephrosis/nonfunctioning kidney 
(unless known due to other cause)
IIIC  Involvement of pelvic and/or paraaortic lymph nodes, irrespective of tumour size 
and extent (with r=radiology and p=pathology notations)
IV IV The carcinoma has extended beyond the true pelvis or has clinically involved the 
mucosa of the bladder and/or rectum. (Biopsy proven)
IVA IVA Spread to adjacent pelvic organs
IVB IVB Spread to distant organs
Table 1. FIGO staging for cervical carcinoma combined 2009 and 2018 where red letters mark 
changes to the system applied 2018. Adapted from (4, 42)
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2.6 TREATMENT
2.6.1 Radical surgery
In the year 1951 Dr. Meigs published data on 100 patients with cervical cancer stage 
I and II. He described a modified radical hysterectomy that had been defined by 
Ernst Wertheim 1912. Meigs had performed abdominal surgery with hysterectomy 
and extended the parametrial dissection to the pelvic sidewall where he stressed 
the importance of systematic lymph node dissection in the pelvis. A five year sur-
vival rate of 89,5% for patients with stage I disease and 63% for patients with stage 
II disease was presented (43). Ever since modifications have been made both on 
the extension of the hysterectomy towards less radical surgery and the operation 
modalities have shifted from open to minimally invasive surgical (MIS) technique. 
With laparoscopic surgery, introduced in the nineties, there was a significantly lon-
ger operation time but the patients lost less blood and had shorter hospital stay 
(44). Despite some advantages for the patients, the method did not gain popularity 
worldwide, probably because of limitation such as a prolonged learning curve for 
the operator, long operation time and ergonomic issues.
Robotic assisted laparoscopic surgery (RALS) was accepted 2005 in the US and rap-
idly became widely accepted and introduced into gynecological oncology. Observa-
tional studies confirmed advantages in form of shorter hospital stay, less bleeding 
and acceptable operation time as compared to conventional laparoscopy (45-47). 
The data on oncological safety consisted until last year of retrospective observa-
tional cohorts of 100-500 patients with a follow up time from 30-60 months. These 
studies are consistent in regards to recurrence rate of 9-13% for patients operated 
on with robotically assisted radical hysterectomy (RRH) with no statistically signifi-
cant difference when compared to abdominal radical hysterectomy (ARH) cohorts 
(48-51). The results from the LACC trial, a phase III, multi-center non-inferiority 
Randomized controlled trial to comparing the outcomes of Laparoscopic Radical 
Hysterectomy (either conventional or robotically assisted) to ARH was published 
last year. The results showed a HR of 3.74 (95% CI 1.63 – 8.58, p = 0.002) for recur-
rences in the laparoscopy group and HR 6.00 (95% CI 1.77 – 20.3, p = 0.004) for OS 
in favor of ARH after a follow up time of 2,5 years. There was no statistically signif-
icant difference between the groups on quality of life or complications (52). These 
shocking results were further strengthened by a register study including almost 
2500 patients in the US showing an increased mortality in women with stages IA2 
and IB1 who were operated with minimally invasive surgery, HR 1.65 (95% CI 1.22 
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- 2.22; p = 0.002) for death after the introduction of RALS (53). These results have 
questioned the modern practice that in most western countries consists of RALS 
as a routine for the treatment of patients with cervical cancer. The criticism on the 
LACC study has been that it mainly consisted of laparoscopic surgery (86%) and not 
RALS (14%) and the low recurrence rates in both these studies do not resemble 
those from previously mentioned retrospective studies. Irrespective of that, as the 
first large prospective randomized trial the results of LACC have to be taken seri-
ously and further studies on RALS and ARH are expected. 
Fertility sparing surgery has been in the treatment arsenal for patients with early 
stage cervical cancer for decades. It has either been performed as a cone biopsy or 
as a radical trachelectomy where the uterine cervix is removed together with sur-
rounding pericervical tissue preserving about 0,5-1 cm of the cranial cervix includ-
ing isthmus uteri that is attached back to the vaginal mucosa. As this procedure is 
relatively uncommon, no randomized controlled trials or large prospective trials 
have been published. The data available are from retrospective series, the largest 
from 2016 that reviewed the literature for patients with stage IA-IIA1 disease. A 
recurrence rate of 5% for abdominal radical trachelectomies from a total of 660 
patients versus 6% in the 238 patients that had been operated by MIS was found 
(54).
In a conclusion ARH with pelvic lymph node dissection is to be considered the 
current gold standard for treatment of patients with early stage cervical cancer. 
Oophorectomy is not recommended unless for patients with larger tumours > 4 cm 
or with other histology than squamous cell carcinoma as metastasis is uncommon 
with squamous cell and smaller tumours of adenocarcinoma (55).
2.6.2 Sentinel node biopsy
Sentinel node biopsy (SNB) is a well-established diagnostic method in oncological 
surgery that identifies the first lymph node in the lymphatic chain from the organ 
of interest. In gynecological tumours it has been substantially studied and since 10 
years adapted for vulvar cancer and recently even endometrial cancer (56-59). The 
main goal of SNB is to retain safe lymph node diagnostics but diminish morbidity by 
omitting complete lymph node dissection in SNB negative patients (60-63). The pre-
requisite for the acceptance of such method is a high diagnostic accuracy and low 
detection failure, where the most important aspect of the diagnostic performance 
would be high sensitivity and high NPV. A new technique based upon fluorescent 
dye, Indocyanine green (ICG), and near infrared imaging has been studied on 
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patients with endometrial and cervical cancer and appears to be both feasible and 
superior to older tracers for sentinel node detection, yielding up to 100% unilateral 
and >90% bilateral SNB (62, 64, 65). Further advance with ICG is the possibility to 
detect and follow the lymphatic vessels to the SNB nodes thereby creating a more 
comprehensive mapping, (Figure 5) (66). In a review from 2015 of the diagnostic 
studies available on SNB for cervical cancer patients the authors concluded that 
pooled sensitivity (n=1275) was 94% and NPV of 91-100%. With a combination of 
following factors: stages IA2-IIA, tumour size < 40 mm, no suspicious metastatic 
disease pre or peroperatively and bilateral negative SNB after ultra-staging (thinner 
slides from the lymph nodes for histological evaluation) there was only 1 false nega-
tive result (0.08%) (67). Due to lack of large prospective randomized trials, the ques-
tion whether lymph node dissection is therapeutic or only diagnostic still remains 
unanswered causing hesitation to abandon the radical lymph node dissection and 
adapt the seemingly reliable SNB technique. 
2.6.3 Radiation and chemotherapy
Radiation therapy is since the 1960´s the cornerstone of treatment for locally 
advanced cervical cancer. To date radiation-chemotherapy (RCT) combining exter-
nal beam radiation therapy (EBRT), concomitant Cisplatin and intracavitary radio-
therapy (brachytherapy) is standard treatment for patients with advanced stages ≥ 
IB2, with some exceptions for selective cases with stage IIA1. A total dosage of EBRT 
45-50 Gy is the standard, given in daily fractions of 1.8-2.0 Gy as this dose has been 
shown to be sufficient to eradicate micro-metastases with acceptable toxicity (68). 
The treatment is directed over the pelvic region covering the genitalia and lymph 
Cervix
Lateral 
parametrium
Lymphatic vessel
Sentinel
lymph node
Figure 5. The lymphatic mapping with near infrared imaging and ICG in a patient with early stage 
cervical cancer. 5a; a trans peritoneal view of the ICG uptake from the backside of the uterine cervix. 
5b; following the lymphatic vessels along the iliac vessels on the right pelvic wall, closest in view an 
ICG positive lymph node.
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nodes, with cranial border around lumbar vertebrae 4-5. Brachytherapy is a key 
component of the radiation therapy to gain local control over the tumour (69). By 
a concentration of high dose radiation centrally around the probe adjacent organs 
can be spared. The treatment is targeted with the help of modern MRI led 3D tech-
nique adjusting the field to shrinking tumour volumes during the treatment period 
(70). In Sweden a total dose of 55-60 Gy divided between (EBRT) and brachytherapy 
is used for patients with metastasis < 2 cm, but a higher total dose of 60-64 Gy 
is recommended for larger metastasis > 2 cm. Furthermore, a boost over lymph 
nodes with suspected metastasis is given (36). Based on the prospective RTOG trial 
(n=402) and data from other prospective trials, the addition of weekly concomitant 
Cisplatin treatment to radiation therapy increases the OS for patients with cervical 
cancer and should be standard of care (71), with recommended 6 cycles of treat-
ment as the number of cycles given < 6 is a predictor for worse survival (72).
2.6.4 Treatment according to disease stage
As previously stated 1/3 of cervical cancer cases in Sweden are found through screen-
ing. In a microscopic disease up to stage IA1 surgery with cone biopsy or simple hys-
terectomy is sufficient, as long as no lymph vascular space invasion (LVSI) is present. 
In stage IA1 with LVSI present, surgical lymph node diagnostics are recommended and 
for IA2 surgery with radical hysterectomy or trachelectomy together with lymph node 
dissection is the treatment of choice, as evidence is lacking for less radical surgery from 
stage IA2 (73, 74). For stage IB1 fertility sparing surgery can be offered in cases of small 
(<20 mm) tumours if no metastases are found in the pelvic lymph nodes and high-risk 
histology such as neuroendocrine tumour is excluded (75, 76). Due to increased risk 
for long term morbidity following RCT, patients with stage IB1 and selective cases of 
IIA1 will be recommended radical hysterectomy and pelvic lymphadenectomy, even 
though primary RCT is reported to be equally effective in this group of patients (77). 
Combined RCT is standard of care for women with disease stage ≥ IB2 in Sweden.
Patients with unfavorable histological features after surgery are subjects to adju-
vant RCT. A metastasis in the lymph nodes and neuroendocrine histological subtype 
are definitive high risk factors. If more than one of following intermediate risk fac-
tors is present: > 1/3 deep stromal invasion, positive LVSI or the tumour size > 4 
cm at histology, adjuvant therapy should be considered even if no metastases are 
found in the lymph nodes (78-80).
All treatment options except fertility sparing surgery for tumours < 2 cm causes 
the patients secondary infertility.
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2.7 PROGNOSTIC FACTORS AND SURVIVAL
The strongest prognostic factor in patients with cervical cancer is the disease stage 
and presence of metastases in the lymph nodes at the time of diagnosis (10, 81). 
Tumour size is also an independent prognostic factor with increasing risk for recur-
rence and lymph node metastases with increasing tumour size (82). A prospective 
cohort study on 366 surgically treated patients with stage IB1 elegantly showed 
that the 5-year recurrence free survival rate decreased significantly with increasing 
tumour size from 94.2% for tumours ≤ 2.0 cm to 82.8% for size 2-4 cm and 67.2% 
for tumours > 4 cm, (p < 0.001) (76). Other factors than lymph node metastases 
affecting survival in early stages have been suggested; (LVSI), depth of invasion to 
the cervical stroma, parametrial invasion, certain histological subtypes and age (78, 
82-86). Results are inconsistent for age and LVSI and it is possible that LVSI and 
depth of stromal invasion are more of a surrogate for the risk for lymph node dis-
semination, than a separate independent risk factors. 
According to FIGO 26th annual report from 1999-2001 including almost 15000 
women worldwide the total 5 year OS irrespective of disease stage was 69.5% 
whereas in the most common stage IB1 survival was 89.5%. For all stages, where 
metastases were found in the lymph nodes, the Hazard Ratio (HR) of death within 
5 years from diagnosis was 3.3 (95% CI 2.8-4.0), for stage IB1 the OS dropped from 
94.5% to 75.9% with findings of lymph node metastases with HR 4.7 (95% CI 3.5-
6.4) for death (10). According to a report from National Board of Health and Welfare 
(Socialstyrelsen) published 2018, the relative 5 year survival is 76.1 % and 10 year 
survival 69.7% for women diagnosed with cervical cancer in Sweden (87).
2.8 DIAGNOSTIC IMAGING
2.8.1 Magnetic resonance imaging and Computed tomography
An overview of numerous studies on MRI for the preoperative evaluation of patients 
with cervical cancer is presented in Table 2. Majority are retrospective single center 
series focusing on the performance of MRI and in some cases even CT with over-
all accuracy (correctly classified cases) of staging using histology as gold standard. 
A good overall accuracy between 77- 90% for MRI with worse performance of CT 
65-75% is reported where MRI has both a high sensitivity and specificity to find 
parametrial disease (88-90). Different statistical methods have been applied for 
tumour visualization in different studies but overall the detection rate lies between 
65-91% (Table 2). At least two of the larger studies reported poorer performance of 
MRI to detect smaller tumours < 10 mm (91, 92).
14
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The ACRIN/GOG study was the first large prospective multicenter study in the US 
to evaluate the accuracy of MRI and CT as compared to clinical staging in patients 
with cervical carcinoma. With intention to include > 450 patients with FIGO sta-
dium ≥ IB planed for surgery the study was closed ahead of schedule with only 208 
patients enrolled because of the increasing reliance on CT and MRI during the clin-
ical workup of patients introducing bias to the preoperative staging and secondly 
due to the slow rate of recruitment. The results showed poor sensitivity 26% of 
FIGO clinical criteria for correctly diagnosed stadium ≥ IIB in operated patients but 
a specificity of 99%, in comparison to CT with a sensitivity of 42% and specificity 
82% while MRI had a sensitivity of 53% and a specificity of 75% with no statisti-
cally significant differences between the methods (92, 93). As the results indicated 
poorer performance for MRI compared to the previous retrospective trials to detect 
parametrial invasion the authors suggested that it could be due to smaller tumours 
included in the ACRIN/GOG study compared to the previous studies, furthermore, 
that MRI performed worse in these cases. This conclusion is supported by Bipat et 
al who in a review of > 50 articles 2003 had questioned the additional role of MRI 
in the staging of early stage disease (94). Similar results came from a retrospective 
study on 101 patients where MRI was reported as equal to CT and not superior to 
clinical examination for staging (95). In a meta-analysis from 2103 comparing MRI 
and clinical staging for advanced stage disease ≥ IIB, the results from 40 studies 
(n=3254 patients) were pooled, showing a sensitivity of 84% vs. 40% and specificity 
92% vs. 93% for parametrial invasion, sensitivity 79% vs. 53% and specificity 93% 
vs. 97% to correctly stage advanced disease (bladder, rectum) for MRI and clinical 
examination respectively (96). For preoperative lymph node assessment MRI has a 
reported sensitivity 24-100% and specificity 84-99%, (Table 2). The performances 
of CT and MRI for detection of metastases in the lymph nodes were similar in these 
studies (89, 92, 97, 98). 
Diffusion weighted imaging has appeared as a complement to conventional MRI. 
It is based on free diffusion of water molecules in tissues and according to some 
evidence increases the accuracy for local assessment (99). Partly by using so called 
Apparent diffusion coefficient that is lower in tumours compared to healthy cervical 
stroma and seems to have a predictive value for finding disease in the parametrium 
as well as for the risk of recurrence (100, 101). Furthermore, the addition of Diffu-
sion-weighted sequences seems to increase the security of evaluation for the less 
experienced MRI reader (102). 
To summarize the above, MRI has been adopted in most western hospitals as part 
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of the routine clinical workup of patients with cervical carcinoma with evidence 
supporting improved diagnostic accuracy especially for advanced disease stages > 
IB1 when compared to FIGO´s clinical criteria alone. There is some inconsistency 
regarding accuracy of tumour detection from different studies indicating worse 
performance for smaller tumours < 10 mm as well as low sensitivity for the evalu-
ation of lymph node metastases (96, 103). Plain CT scan in the diagnostic work-up 
of patients with cervical carcinoma is unmotivated as no obvious advantages are 
gained with CT as compared to MRI for this patient group (94).
2.8.2 Positron emission tomography (PET)
PET performed with 2-fluoro-2-deoxy-D-glucose labeled with the positron emit-
ter fluorine-18 is a molecular functional imaging modality (FDG PET/CT). Through 
increased glucose metabolism of cancer cells it enables detection of metastases > 
5mm in size that otherwise would not be considered pathological on plain CT or 
MRI (107). However, FDG PET/CT has limited value in the primary staging of low vol-
ume local disease in patients with early stage cervical cancer, even when micro-me-
tastases are present (108). According to a meta-analysis from 2017 the accuracy for 
detecting lymph nodes metastasis with PET/CT (n=22 studies) is higher in advanced 
stage disease as compared to early stage disease (AUC 0.95 versus AUC 0.76, p = 
0.03) (109). In Sweden PET/CT is recommended as a complementary examination 
for patients where advanced disease is suspected.
2.8.3 Ultrasound
In 1950 John Julian Wild with coworkers published an article on unidirectional 
A-mode ultrasound waves to explore the thickness of surgical intestinal material 
(110, 111). During their research Wild and Donald Neal learned that malignant tis-
sue in the bowel had a hyper echoic character seen with ultrasound waves and did 
not contract and relax in the same manner as healthy bowel (110, 112). Some years 
later or 1958 when diagnostic scanners had been developed Professor Ian Donald 
presented his research in the Lancet about investigation of abdominal masses by 
Pulsed Ultrasound, thereby introducing the method in Obstetrics and gynecology 
(110, 113). Ultrasound is now the most widely available and thoroughly studied 
imaging modality used by obstetrician and gynecologists around the globe. The 
technique is introduced to all trainees from the first day working in the field. Com-
pared to MRI ultrasound has both some advantages and disadvantages. In regard 
to the diseases in the pelvis a closer look and more dynamic image is achieved, 
being able to adjust the image quality in real time and zoom in on areas of inter-
17
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est. For the patient it is safe with few or any contraindications other than possible 
discomfort during the examination. The negative aspects are the difficulties in stan-
dardizing image acquisition, as this is operator dependent. Moreover, transvaginal 
ultrasound must be complemented by transabdominal scanning to get an overview 
of the pelvis in the manner that is possible by MRI or CT. 
2.8.4 Ultrasound on patients with cervical cancer
In a case report from may 1992 the authors describe the aid in using transvaginal 
ultrasonography (TVS) in the staging of a woman with cervical cancer as the ultra-
sound revealed parametrial involvement and lymph node metastases in the pelvis, 
not found by clinical palpation (114). That same year Innocenti and coworkers pub-
lished a prospective study on a cohort of 124 women with surgically treated cervi-
cal cancer. For the extent of parametrial involvement, the sensitivity of ultrasound 
evaluation was 78% and the specificity 89% compared to clinical evaluation with 
sensitivity 52% and specificity 92% (115). Since then the ultrasonography technique 
has improved dramatically with high quality grayscale imaging available as well as 
additional modalities such as Doppler, 3D US and CEUS. 
Testa and co-workers found that vascularity was seen in nearly all lesions of cervi-
cal cancer (116) with both two dimensional (2D) color Doppler and 3D, confirming 
Alcazar’s previous results on high blood flow mainly in squamous cell types and 
poorly differentiated lesions (117). In 2010 Epstein and colleagues related differ-
ent histology types of cervical cancer to findings with TVS where adenocarcinomas 
were more difficult to see with grayscale ultrasound compared to squamous cell 
cancer because the lesions were iso-echoic to the surrounding normal tissue (Figure 
6). Further results were that virtually all tumours in the uterine cervix were richly 
vascularized which facilitated detection and assessment (118). To further study the 
agreement between TVS prior to surgery and histology after surgery Gaurilcikas 
with co-workers published a prospective series on 18 patients with FIGO stage IB1-
IIA cervical cancer. They found good agreement for tumour size and parametrial 
infiltration (100%) but a worse correlation for the assessment of tumour invasion of 
the cervical stroma (119). 
In order to standardize the evaluation of patients with cervical cancer, Fischerova 
wrote a review article describing a method for ultrasonography examination of 
these patients (120). The importance of adequate equipment is stressed as well as 
the knowledge on the expected dissemination pattern. By performing a structured 
examination all the important aspects of tumour dissemination are covered. The 
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recommended probe is a micro 
convex array probe either trans-
vaginally or transrectally to eval-
uate if tumour is seen or not; fol-
lowed by description of the growth 
pattern; exophytic or infiltrative. 
Measurements are done in three 
dimensions (cervico-fundal, ante-
rio-posterior and lateral), in cases 
when fertility sparing surgery is 
considered the distance of the cra-
nial tumour boarder to the inter-
nal cervical os is measured. The 
depth of stromal invasion (≤ 1/3 
or 2/3 or > 1/3 or 2/3) is assessed 
as well as the involvement of the 
parametrium when the pericervi-
cal fascia is disrupted. Parametrial 
invasion can be graded according 
to Figure 7. Power Doppler exam-
ination should complement the 
grayscale image to estimate the 
amount of vascularization with 
color score. Finally, assessment 
of overgrowth onto adjacent pel-
vic organs, hydroureters, hydro-
nephrosis and any bulky pelvic, 
paraortic, inguinal lymph nodes 
is done by combining systematic 
transrectal/transvaginal ultra-
sound examination with trans 
abdominal scanning using a linear 
probe (120). For the US examina-
tion of the patients included in the 
studies of this thesis, Fischerovas 
method was followed.
Tumour
Cervical 
stroma
Parametrial 
invasion Maintained
Pericervical
Fascia
Patients right side
Figure 6. A 63 years old woman with cervical cancer, 
stage IIB. 6a: US grayscale image in sagittal plane 
showing hypoechoic tumour filling out almost the whole 
cervix with minimal cervical stroma seen on the back 
side 6b:Transverse section of the same tumour show-
ing parametrial invasion on the patients right side but 
maintained paracervical fascia on the patients left side 
(arrow) (arrow). 6c: 2D power Doppler in sagital plane, 
abundant vascularization the indicates invasion anteri-
orly towards the bladder. 
a)
b)
c)
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2.8.4.1 Ultrasound and MRI
There are several studies published comparing the accuracy of MRI and US in 
patients with early stage disease, the most relevant results are summarized in Table 
3. The three largest prospective studies have all presented similar results on tumour 
detection rate. In a study on 68 patients, Testa and colleagues found 93% detection 
rate of tumour with US compared to 88% on the MRI, further they found similar 
accuracy of the methods for assessment of deep stromal and parametrial invasion 
(Table 2 and 3) (105). In Fischerova and colleagues paper on 95 surgically treated 
patients they found that TRS was better than MRI at detecting small tumors with 
Figure 7. Grading of parametrial infiltration by transvaginal/transrectal sonography. (a–c) Schematic 
diagrams showing: (a) intact pericervical fascia (PCF) (Grade 0), lateral parametria (lateral p.) and 
PCF; (b) parametrial infiltration Grade 1 (disrupted PCF but without progression through the fas-
cia into parametria) and Grade 2 (incipient infiltration of PCF); note that the incipient infiltration is 
characterized by discrete breaks in the PCF with very fine hypoechogenic prominences into the 
parametria; (c) nodular infiltration (Grade 3) and discontinuous parametrial infiltration (Grade 4). (d–i) 
Ultrasound images showing: (d) in the sagittal view, hyperechogenic PCF (Grade 0) located between 
the cervix and hyperechogenic bladder visceral fascia (black dashed line corresponds to the vesi-
cocervical space also known as the septum); (g) in the transverse view, intact PCF surrounding the 
cervical stroma dorsally; (e,f,h,i) parametrial infiltration Grades 1–4. Reprinted with permission from 
Ultrasound in Obstetrics and Gynecology Vol. 38, No. 3: 246-266.
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detection rates 90% versus 81% for tumors <10 mm (p=0.05), whereas for parame-
trial invasion equal specificity (100 vs. 98%) but higher sensitivity (83% vs. 50%) was 
detected for US (104). Further data from a larger multicenter study by Epstein and 
coworkers on 182 women with early stage disease strengthens the evidence for 
the high accuracy of US for tumour visualization, reporting that ultrasound is equal 
or better than MRI in detecting residual tumors even after cone biopsy, for deep 
stromal and parametrial invasion, however, as in Testa´s study both modalities were 
limited for the diagnostics of lymph node metastases (1, 105). 
There are few studies published on the performance of conventional US on patients 
with advanced disease stages. The PRICE study included 88 women with diseases 
stages IB2-IVA who received neoadjuvant RCT therapy before surgical treatment. 
US examination with 2D, 3D and CEUS were performed before and after neoad-
juvant treatment to evaluate if any US modality was useful to monitor treatment 
response and detect residual disease after NACT. None of the different modalities 
turned out accurate enough to detect microscopic residual disease, of all modali-
ties 2D US with power Doppler had the best performance with sensitivity 63% and 
specificity 70% (121).
2.8.4.2 Three dimensional ultrasonography (3D)
When the three-dimensional ultrasound vaginal probes emerged there were hopes 
on its usefulness on gynecological patients. The examination is done in the same 
manner as TVS where images are collected through one plane with 2D US. Before 
collecting the volume the image is optimized with the organ of interest is centered 
centrally located. The volume is then acquired through automated sweep holding 
the probe completely still. The quality of the volume is dependent on the quality 
of the 2D image, motion artifacts, the size of the volume and the number of voxels 
which are factors that can be adjusted before the sweeping is done (122). The res-
olution in the collected plane is always good, but the quality of the reconstructed 
plane is highly dependent on the quality of the volume collected. From the volume 
planes that can normally not be seen with 2D, reconstructed planes are built such 
as the important coronary view. By using 3D power Doppler the vascular tree can be 
visualized in three dimensions with a possibility of removing the grayscale echoes 
(123). The vascularization within a volume can be assessed with three-dimensional 
power-Doppler (3D-PD) by calculating the vascularization index (VI), vasculariza-
tion-flow index (VFI) and flow index (FI) with the help of software package. There 
is some uncertainty on what exactly is measured by 3D-PD but VI is supposed to 
21
The role of new ultrasound modalities to refine the diagnostic workup on women with cervical carcinoma
Ta
bl
e 
3.
 O
ve
rv
iew
 o
f t
he
 m
ain
 st
ud
ies
 o
n 
th
e 
ac
cu
ra
cy
 o
f u
ltr
as
on
og
ra
ph
y f
or
 th
e 
as
se
ss
m
en
t o
f p
at
ien
ts
 w
ith
 e
ar
ly 
st
ag
e 
ce
rv
ica
l c
an
ce
r. 
Da
ta
 a
da
pt
ed
 fr
om
 (1
, 1
04
-1
06
, 1
15
)
Tu
m
or
	d
et
ec
ti
on
St
ro
m
al
	in
va
si
on
St
ag
in
g
Pa
ra
m
et
ri
um
Ly
m
ph
	n
od
es
Fi
rs
t	
au
th
or
Ye
ar
	
n
St
ud
y 
ty
pe
Ac
cu
ra
cy
 
Ac
cu
ra
cy
Ac
cu
ra
cy
Se
ns
Sp
ec
Ac
cu
ra
cy
Se
ns
Sp
ec
Ac
cu
ra
cy
In
no
ce
nti
19
92
12
4
P
N
/A
N
/A
83
%
78
%
89
%
87
%
N
/A
N
/A
N
/A
Fi
sc
he
ro
va
20
08
95
P
94
%
N
/A
N
/A
83
%
10
0%
99
%
N
/A
N
/A
N
/A
Te
st
a
20
09
68
P
se
ns
 9
3%
, s
pe
c 
50
%
se
ns
 1
00
%
, s
pe
c 
75
%
N
/A
60
%
89
%
87
%
9%
10
0%
82
%
Ep
st
ei
n
20
13
18
2
P
se
ns
 9
0%
, s
pe
c 
97
%
se
ns
 8
8%
, s
pe
c 
93
%
N
/A
77
%
98
%
97
%
8%
N
/A
N
/A
M
ol
on
ey
20
16
33
P
N
/A
se
ns
 8
0%
, s
pe
c 
50
%
N
/A
20
%
89
%
79
%
N
/A
N
/A
N
/A
A
cc
ur
ac
y:
 c
or
re
ct
ly
 c
la
ss
ifi
ed
 c
as
es
 / 
to
ta
l n
um
be
r o
f c
as
es
, s
en
s 
= 
se
ns
iti
vi
ty
, s
pe
c 
= 
sp
ec
ifi
ci
ty
, p
= 
pr
os
pe
ct
iv
e,
 N
/A
 =
 N
ot
 a
ss
es
se
d
22
Kolbrún Pálsdóttir
quantify the number of color voxels in a volume indicating the density of vessels 
in the tissue of interest. FI represents the intensity of flow in the region of interest 
(ROI) at the time of the three-dimensional examination. VFI is a combination of 
vascularization and flow information (124, 125). 
As already discussed in previous chapter cervical tumours are richly vascularized 
in contrast to the fibrotic cervical stroma. There is substantial research done on 
the vascularity aspect of 3D US where it has been confirmed that all three vascu-
larity indices are higher in patients with invasive cervical carcinoma as compared 
to healthy cervical tissue (116, 126-128). Two studies have focused on the rela-
tionship between vascularization, vascularity indices and prognostic histo-patho-
logical factors where the results suggested higher 3D-PD vascularity indices in more 
advanced tumours, furthermore, higher vascular indices in poorly differentiated 
tumours (126, 127). Despite that, no correlation was found between 3D-PD indices 
and lymph node metastases in neither of these studies. Even if these studies were 
relatively small, the results were consistent regarding vascularity indices and lymph 
node metastases. No study has yet evaluated 3D parameters for the prediction of 
deep stromal invasion or parametrial invasion. Research on 3D US and cervical can-
cer has focused as well on the possible predictive value for patients that are subject 
to NACT before surgery or primary RCT with negative results. FI was suggested as a 
predictive marker for NACT responders, (129) however, neither in the prospective 
PRICE study nor another smaller study were 3D vascular indices found useful to 
monitor response to NACT or RCT in patients with advanced disease (121, 130).
Limited but promising results are available on the accuracy of 3D US for staging. In 
a small sample of 24 patients with locally advanced disease, 3D US had comparable 
overall accuracy to MRI 62.5% versus 66.7% respectively with histology as gold stan-
dard (131). Chiappa and colleagues examined 29 patients using MRI as a reference 
standard and found a comparable, moderate correlation between 2D US, 3D US 
and MRI with the best agreement (81%) in evaluating right lateral parametrium in 
the middle part of the cervix (132). Still another study on 40 patients reported 80% 
overall agreement for parametrial invasion between 3D US and MRI with a κ =0.60 
and very good κ = 0.84 with 97.5% agreement for bladder involvement (133).
2.8.4.3 Contrast enhanced ultrasonography (CEUS)
CEUS makes it possible to see small blood vessels not visualized with conventional 
2D PD US (134). Tumours are characterized by neovascularization and it has been 
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documented that cervical tumours are often well vascularized making the CEUS par-
ticularly interesting for tumour evaluation. There are a couple of different contrast 
agents available but SonoVue ® is by far the most commonly used one with a well doc-
umented safety profile (135, 136). It is composed of a gas micro bubbles containing 
Sulphur hexafluoride, stabilized by a monolayer of phospholipids. It is administrated 
intravenously as a bolus followed by saline injection and during a window of 2-3 min-
utes ultrasound videos are collected with a split screen for the contrast view and the 
usual B-mode view (137). The interpretation and recording of CEUS images demands 
special software installed on the ultrasound machine. The contrast agent is cleared 
from the body through the lungs with breathing and does not affect the kidneys or 
liver. CEUS has improved the diagnosis of liver tumours, mostly in the differential 
diagnosis between metastatic lesions and benign lesions (138-140). According to the 
European federation of societies for ultrasound in medicine and biology (EFSUMB) 
there are no established indications for using CEUS in gynecological diagnostics to 
date and the clinical value of the method in the assessment of cervical tumours is 
uncertain (141). Testa and colleagues did a small descriptive study including 10 
patients with cervical carcinoma examined with CEUS, where the method improved 
the demarcation of the tumour borders in 40% of cases (142). When the work started 
on this thesis, no studies were available on the contrast kinetics in patients with cer-
vical cancer and as CEUS has a potential as a surrogate for vascularization in tumour 
tissue, it was important to further explore the method.
Since then two publication have emerged both from Zheng and colleagues showing 
that contrast kinetics are different in tumorous tissue compared to myometrium in 
the uterus, moreover, that micro vascular density found on histological examina-
tion after surgery correlates to higher contrast intensity as measured by CEUS. In 
a recently published paper CEUS (abdominal probe) was compared to MRI in the 
evaluation of local invasion of cervical cancer in 108 patients with advanced stages 
IIA2-IVB. The results showed a strong correlation in size measurements r=0.84-0.88 
between the two methods and a moderate (parametrial, vagina) to good (uterine 
corpus, bladder and rectum) concordance for the evaluation of local spreading to 
adjacent organs (143). 
2.8.4.4 Strain Elastography
Ultrasound strain elastography (SE) is a technique that was proposed in the nineties 
by Ophir and colleagues as a complement to conventional ultrasonography (144). 
Taking advantage of the different compliance of human tissue the technique col-
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lects information on the elasticity of the tissue examined. In a simplified way it can 
extract the findings of clinical palpation into an image thereby more objectively 
quantify the clinical findings. The image of 2D SE is presented with color range 
superimposed on a grayscale ultrasound image, (Figure 8) where differences in tis-
sue strain appear with different colors. Red is the softest tissue that changes form 
with pressure, blue is the hardest with the least strain and green is in between (145). 
With extra software package, further semi-quantitative analysis on the SE images is 
possible such as calculating strain ratio or size ratio as compared to B-mode images. 
SE has been extensively examined in patients with breast cancer where it can com-
plement the conventional B-mode US to differentiate between benign and malig-
nant lesions (146-148). Furthermore SE in addition to conventional US seems to 
increase accuracy of targeted biopsies in patients with suspected prostate cancer 
(149, 150). Thomas and colleagues studied uterine cervixes in healthy women and 
women with cervical cancer (n=113) and found that normal healthy cervical tissue 
is of medium hardness and stays unchanged with age. They concluded that the SE 
helped to outline malignant tumours from healthy tissue as there was a signifi-
cant difference in stiffness of the tumour lesions (151). This finding was confirmed 
with the results of Lu and colleagues who in a prospective study on a mixed group 
of 84 women with benign and malignant tumours in the uterine cervix showed a 
Figure 8. Strain elastography image from an examination of a patient with stage IB1 cervical cancer. 
Cervical stromal tissue and tumour are seen with different shades of blue with the softer surround-
ing tissue in red and green colors. The grayscale image is used in the background to build on the 
elastography images. 
Cervical stroma Tumour
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positive predictive value (PPV) of 85,7% and negative predictive value (NPV) 81,0% 
for higher elasticity score 4-5 to distinguish malignancy from benign disease. They 
further tested strain ratio with promising result of around 90% PPV and NPV for a 
cut-off 4.525 to distinguish between malign and benign lesions in uterine cervices, 
thereby confirming the same cut-off ratio that had been suggested by Sun and col-
leagues from a previous prospective series of over 100 patients with mixed cervical 
lesions (152). A feasibility study on the SE examination of 36 patients with locally 
advanced cervical cancer before and after combined RCT showed that the patients 
with complete response after given treatment had greater decrease in strain ratio 
during and after treatment compared to those who were partial responders (153). 
No studies have compared the accuracy of tumour assessment locally in the pel-
vis with SE, neither subjective evaluation or size measurements compared with US 
alone. 
2.8.5 Reproducibility 
For all different diagnostic imaging, inter-observer reproducibility is a concern. 
Most studies report the accuracy of one or two different readers where reproduc-
ibility is not always evaluated. At least two prospective studies have confirmed a 
good inter-observer and intra-observer agreement for 3D US in cervical cancer 
patients for measurements of vascularity indices (154, 155). In the ACRIN/GOG 
study, inter-rater reliability was moderate for staging (κ=0.44), fair for tumour 
visualization (κ=0.32) and poor for parametrial invasion (κ=0.11) with retrospec-
tive readings by four experts on MRI (156). No published studies on inter-rater 
reliability (reproducibility) for conventional 2D US or studies comparing the 
reproducibility of MRI and US for diagnostic evaluation of women with cervical 
cancer have been identified.
2.9 SUMMARY
The staging of newly diagnosed patients with cervical cancer remains a challenge 
as a result of the inadequate clinically based staging system and because available 
diagnostic imaging methods are insufficient to complete the clinical system. There 
is substantial evidence for high accuracy of US assessment with regard to tumour 
visualization, evaluation of deep stromal invasion and there seems to be a high sen-
sitivity for finding parametrial infiltration in women with early stage cervical cancer. 
For obvious reasons, there is scares evidence for the accuracy of all imaging modal-
ities with regard to assessing advanced disease, as these women will not undergo 
surgery. Due to a good overview of the pelvis, high tissue resolution and evidence 
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for its accuracy, MRI has become the complementary method of choice for cervical 
cancer patients both for treatment triage as well as being an important instrument 
guiding the 3D brachytherapy (157). The availability of MRI however, remains lim-
ited in low resource countries where the incidence of cervical cancer is high (5). 
The method has its limitations just as the US, such as a tendency to overestimate 
the size of smallest tumours in the cervix as well as missing 20% or more of lymph 
node metastases even with the added Diffusion weighted sequences (1, 92, 158). 
Another diagnostic dilemma is when surgical margins from a diagnostic cone biopsy 
are not disease free, the patient will be assigned stage IB1 even if no macroscopic 
lesion can be identified. In these cases, assessment of residual disease by imaging 
or clinical examination is difficult. The patients are according to the actual recom-
mendations often going through more extensive surgery than necessary. This is an 
important group, as in Sweden about 35% of the patients are still in reproductive 
age where some strongly wish to preserve fertility. For this reason it is important to 
further study the value of CEUS or SE in addition to conventional US on the smallest 
tumours in terms of characteristics and accuracy. It would also be an advantage to 
be able to predict which patients are at increased risk for lymph node metastases by 
identifying some preoperative factors on US. To explore the full potential of ultra-
sound for patients with cervical cancer it is important to examine if new modalities 
are applicable in our settings, what are the most beneficial aspects of the methods, 
furthermore, to examine if US and MRI are comparable in terms of reproducibility 
for local tumour assessment. 
2.10 METHODOLOGY IN DIAGNOSTIC STUDIES
2.10.1 Sensitivity/specificity
Diagnostic studies aim to evaluate the potential of a test to separate a diseased 
from non-diseased objects. The term accuracy refers to the ability of the test to 
correctly find the objects that truly have a condition (true positive) and those who 
truly don´t have the condition (true negative). The test under evaluation is referred 
to as index	test and to be able to assess it´s accuracy an accepted standardized test 
is used as the reference	test, often the gold standard within the field of interest. 
There are different ways to present the accuracy of test. The ability of a test to find a 
disease or a condition is called sensitivity whereas the ability of the test to separate 
the objects without disease from the rest is called specificity. A predictive value 
can be calculated both negative and positive that describes the index test ability to 
predict the value of positive or negative results in a certain population. The prev-
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alence of the disease in the population assessed affects the positive and negative 
predictive value and to a less extends the sensitivity and specificity of the index test 
under evaluation. A test that works well in a selective population of patients may 
not at all be applicable as a screening test where the prevalence is low. The perfect 
test would have 100% sensitivity and specificity, which is rarely the case. Depending 
on the indication for the test a compromise has to be done between the two. A 
common way to present the results in a diagnostic accuracy study is by a 2x2 table 
where the reader can calculate sensitivity, specificity, PPV and NPV;
Another way to refer to accuracy is by correctly classified cases where the total 
number of true negative and true positive cases is divided by the total number of 
cases
2.10.2 Receiver operator characteristics (ROC curve)
To compare the diagnostic accuracy of two or more different tests the sensitivity and 
specificity can be plotted on a graph with the sensitivity on the y-axis and 1-spec-
ificity (false positive rates) on the x-axis, called a Receiver operator characteristics 
(ROC) curve. A diagonal line (reference line) runs in the middle of the graph, tests 
that lie to the left of the line are better than chance. The best test would have a 
curve up in the left corner. For each test it is possible to calculate the Area under the 
curve that represents the overall accuracy of that test. The closer the AUC gets to 1 
the higher accuracy for the test. For every single cut-off point on the curve there is 
a sensitivity and specificity (Figure 9). 
REFERENCE TEST
INDEX TEST YES NO
YES True	positive	(TP) False	positive	(FP) PPV = TP/TP+FP
NO False	negative	(FN) True	negative	(TN) NPV = TN/
TN+FN
Sensitivity =TP/TP+FN Specificity = TN/TN+FP
Accuracy (correctly classified cases) =        TP+TN
      TP+FP+TN+FN
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The choice of cut-off point is a trade-off between sensitivity and specificity depen-
dent on what is the most important aspect of the index test. The point that is fur-
thest to the left from the reference line can be referred to statistically as optimal 
cut-off where you get as high possible sensitivity and specificity, this may however 
not reflect the optimal cut-off point from a clinical perspective.
2.10.3 Statistical tests
To answer a research question a sample from a population is studied. The null 
hypothesis (H0) is usually that there is no difference between the study sample 
and the whole population. The alternative hypothesis (HA) would be that there is 
a difference. To be able to test your hypothesis a level for significance needs to be 
set that usually is chosen at 5%. This level marks the risk of making a type I error in 
the study and to reject the H0 even if it is true. There are number of different sta-
tistical tests to use and the outcome being studied is of greatest importance when 
choosing appropriate test as well as the distribution of the data being tested. In a 
normally distributed data most usual for continuous outcome the test of choice is 
students t-test while Mann-Whitney would be applied in a non-normally distributed 
Figure 9. ROC curve showing an example of a test with average AUC the curved line. The dotted 
diagonal reference line refers to a useless test. Reprinted with permission from (159)
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continuous data. Chi-square test is used to test hypothesis for ordinal or nominal 
outcome except when testing unusual outcome or when samples are small fisher´s 
exact should be applied instead. A good test for binomial data is McNemar. Differ-
ent statistical methods can also be used to compare means or medians between 
groups where the choice of test follows the same rules as stated above. 
2.10.4 Kappa statistics
When reproducibility of a test or inter-rater reliability is evaluated, it is possible to 
calculate the overall agreement between two raters as a proportion of the number 
of cases evaluated. (Po= Cases agreed between 2 raters / total number of cases) 
However, that does not take into account any skewness, i.e. if the raters agree more 
on the positive cases or the negative cases. Neither does it consider that agreement 
between raters can occur by chance (160).
Kappa statistics is a more robust way to calculate agreement as it takes into con-
sideration the part of the agreement between raters that is likely to have occurred 
by chance. The proportion of agreement due to chance = (proportion of positive 
tests by both observers) 2 + (the proportion of the agreed negative tests by both 
observers)2.
The equation for Cohen	Kappa	(κ) that applies when comparing 2 raters is: 
κ = proportion of agreed cases – probability of agreement due to chance
 1–probability of agreement due to chance
Fleiss	Kappa is comparable to Cohen Kappa but takes into account multiple raters 
and not only a pair of two (161).
The results of κ are between -1 and 1 but are interpreted for values > 0 according to 
Brennan and Silman as follows (162):
An assumption for the application of Kappa statistics is that the raters use the same 
method to assess the same or different cases. It should not be used to compare 
the agreement between raters using different modalities as the methods may have 
different sensitivity and specificity that introduces bias to the measurements.
Poor agreement  < 0.20
Fair  0.21-0.40
Moderate  0.41-0.60
Good  0.61-0.80
Very good  0.81-1.00
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2.10.5 Bland-Altman plot
It was suggested by Altman and Bland in an article in The Lancet 1986 that correla-
tion was not the best way to assess if two different methods had good agreement as 
there is often correlation found even with substantial differences in measurements 
by the methods evaluated. Instead, they suggested a simple way to graphically illus-
trate what the mean difference (systematic error) between methods is and how the 
difference for each individual measurement is distributed (random error) between 
± 2 SD (95% limits of agreement) from the mean difference. A good agreement has 
a mean difference as close to 0 as possible representing no bias. If the difference 
between the measurements of the two methods falls within 95% limits of agree-
ment the precision of the test under evaluation is good (163).
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3 AIMS OF THE THESIS
The main overall objective was to improve the diagnostic assessment of cervical 
tumours in order to optimize and tailor the treatment of each patient. By exploring 
new ultrasound techniques for the assessment of cervical carcinoma in addition to 
conventional ultrasound, the specific aims were to study:
1) How well objective 2D and three dimensional ultrasound (3D US) parameters 
predict deep stromal or parametrial invasion and lymph node metastases, 
compared to subjective assessment in women with cervical cancer undergoing 
surgery.
2) The filling pattern, reproducibility and semi-quantitative parameters of con-
trast-enhanced ultrasound in healthy controls as compared to patients with 
cervical carcinoma, in addition assess if differences were seen in tumours of 
various stages.
3) If ultrasound strain elastography could help to more precisely detect and 
demarcate cervical tumours and evaluate if differences were found in strain 
elastography features in patients with early and advanced stages. 
4) If ultrasound had the same inter-observer reproducibility as MRI in the evalua-
tion of patients with cervical carcinoma.
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4 PATIENTS AND METHODS
4.1 STUDY POPULATION
There are two study populations behind this thesis. One international multi-center 
cohort for study I, including patients from our institution and another cohort only 
from our institution for study II-IV.
4.1.1 Study population I
The study population was collected from December 2007 until October 2012 from 
five European Institutions in three countries. It consisted of 104 patients with his-
tologically confirmed cervical cancer, according to FIGO´s classification disease 
stage I-IIB. Exclusion criteria were women with microscopic tumours that could not 
be identified on TVS or TRS and women that were not eligible for primary radical 
surgery. The clinical characteristics of the study cohort are presented in Table 4. 
The participating centers were the ultrasound unit at the Department of Obstetrics 
and Gynecology, Lund University Hospital, Lund and Karolinska University Hospital, 
Stockholm Sweden; the Gynecological Oncology Center, Department of Obstetrics 
and Gynecology, General University Hospital, Prague, Czech Republic; the Depart-
ment of Oncology, Catholic University of the Sacred Heart, Rome and the Gyneco-
logical Oncology unit, Division of Gynecology, IOE, Milan, Italy. 
Characteristics Number	(%)
Clinical stage*
IA2 7(8)
IB1 81 (78)
IB2 12 (12)
IIA 3 (3)
IIB 1 (1)
Histology
Squamous 66 (60)
Adenocarcinoma 38 (37)
Adenosquamous 4 (3)
Treatment
Hysterectomy 94/104 (90)
Trachelectomy 5/104 (5)
Lymph node dissection 104/104 (100)
Radiochemotherapy 5/104 (5)
*according to FIGO 2009
Table 4. Characteristics of study participants, cohort I (n=104)
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4.1.2  Study population II
The cohort from Karolinska University Hospital generating patients to all of the stud-
ies behind this thesis consisted of 93 women with biopsy verified invasive cervical 
cancer, referred to Karolinska University Hospital for treatment from July 2011 until 
September 2015. During this time 483 women were diagnosed with invasive cer-
vical cancer in region Stockholm/Gotland according to Swedish Quality Registry of 
Gynecologic Cancer (32). All women in the region who are diagnosed with cervical 
cancer are referred to the institution for treatment and were therefore considered 
eligible. Women with all disease stages were considered for inclusion. Of the eligi-
ble 96 accepted participation. Three were excluded as final histology showed other 
disease than cervical cancer, (Figure 10). In Table 5, the characteristics of the study 
participants are presented. The median age was 45 years, majority 62% (58/93) 
had disease stage ≤ IB1 and 67% (62/93) had a squamous cell histology. Included in 
study II there was also a cohort of 21 healthy women who were recruited through 
an advert amongst hospital personnel at Karolinska University Hospital. 
Figure 10. Flowchart of the study population II
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4.2 METHODS
The details of the methods applied for every study in this thesis is described in the 
papers attached. Presented here is an overview.
4.2.1 Study I
4.2.1.1 Study design and objectives:
Design: A prospective European multi-center diagnostic trial of 104 women with 
surgically resectable cervical cancer.
Objectives: To determine the clinical value of various objective 2D and 3D ultra-
sound parameters in comparison to subjective assessment to predict deep stromal 
and parametrial tumour invasion and lymph node involvement in women with cer-
vical cancer scheduled for surgery.
Characteristics
Whole	cohort
(n=93)
Study II
(n=49)
Study III
(n=30)
Study IV
(n=60)
Age* 45 (24-85) 43 (24-76) 47 (26-71) 46 (24-85)
Clinical stage**
Earlys stages: 58 (62) 35 (71) 20 (67) 36 (60)
IA1 7 3 1 1 
IA2 4 4 - 1 
IB1 47 28 19 34 
Advanced stages: 35 (38) 14 (29) 10 (33) 24 (40)
IB2 1 1 - 1 
IIA 9 5 3 7 
IIB 14 5 5 13 
IIIB 8 2 1 2 
IV 3 1 1 1 
Histology
Squamous 62 (67) 30 (61) 21 (70) 40 (67)
Adenocarcinoma 27 (29) 19 (39) 9 (30) 18 (30)
Adenosquamous 2 (2) - -
Other 2 (2) - 2 (3)
Treatment
Surgery 52 (56) 31(63.3) 18 (60) 31 (52)
Radiochemotherapy 41 (44) 18 (36.7) 12 (40) 29 (48)
*median (range),**according to FIGO 2009, the numbers are count (%)
Table 5. Characteristics of the study participants, cohort II (n=93)
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4.2.1.2 Methods
The patients were staged according to FIGOs criteria for cervical cancer. The pri-
mary inclusion critera was surgically resectable disease and tumour seen with TVS 
or TRS. Most centers included only patients with disease stage IB1 or less, other 
centers accepted selected cases with more advanced tumours (stage IB2-IIB) for 
surgery (Table 4). The final histological diagnosis by reference pathologist at each 
center was based on tissue from radical surgery and lymphadenectomy, serving as 
gold standard. 
4.2.1.3 Ultrasound examination
Examination and US systems
US examinations were performed with high-end systems by US experts (n=1-2) at 
each center prior to surgical treatment. All patients were examined with TVS or 
TRS in a lithotomy position with an empty bladder, scanning was done in sagittal 
and transverse planes. Still images with measurements, videos of the conventional 
grayscale, Power Doppler ultrasound examination, 3D grayscale and Power Doppler 
US were recorded at the same occasion for each patient. The results of the con-
ventional grayscale US were assessed at the time of examination whereas the 3D 
volumes were retrospectively analyzed after completion of the study. 
2D ultrasound and power Doppler
On the images from conventional 2D ultrasound the size of the tumour was mea-
sured, subjective assessment of the local extension of the disease, and presence of 
enlarged lymph nodes was evaluated. To begin with, the uterine cervix was central-
ized in the image. Secondly, the tumour was identified, often with help of power 
Doppler additionally to the grayscale. After identifying the tumour it was measured 
in three dimensions in millimeters; cervical fundal diameter, anteroposterior diam-
eter and lateral diameter was measured where the tumour was largest. The tumour 
vascularization was subjectively classified during real time 2D power doppler ultra-
sound examination, using a color score: absent (=1), minimal (=2), moderate (=3), 
or high (=4), as introduced by the IOTA group for the assessment of ovarian mass 
vascularity (164) (Figure 6). The depth of stromal (>2/3) and presence of parame-
trial invasion (yes/no) was assessed at the level of the entry of the uterine arteries 
in both sagittal and transverse plane. If the tumour invaded through the pericervical 
fascia, parametrial involvement was suspected (120). Lymph node stations in the 
pelvis were scanned with abdominal US in addition to TVS / TRS.
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3D ultrasound
After closure of the study the software program 4D view (GE) or QLAB (Philips) was 
used to calculate the volume of the tumour, vascularization index (VI), flow index 
(FI) and vascularization-flow index (VFI). The 3D volume calculation was done using 
15 degrees rotational steps. Figure 11 is an example of a still image from the the 3D 
power Doppler view in a transverse plane in a patient with cervical cancer. 
Histological examination
Local reference pathologist at each center performed histological examination 
according to a predetermined protocol. The examination included assessment of 
tumour type, size, location, presence of > 2/3 of deep stromal and parametrial inva-
sion, as well as assessment of lymph node metastasis. 
4.2.2 Study II-IV
4.2.2.1 Study design and objectives
Study II 
Design: A prospective single center pilot study including 49 patients with all stages 
of cervical cancer and 21 healthy controls. 
Objectives: To describe contrast enhanced ultrasonography (CEUS) filling pattern 
Figure 11. An image from a 3D PD volume, showing the vascularization of tumorous tissue from 
different angles.
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and semi-quantitative parameters in women with different stages of cervical cancer 
as compared to healthy controls. Furthermore, to assess the diagnostic accuracy 
and reproducibility of CEUS filling pattern as compared to conventional ultrasonog-
raphy (US) for cervical tumour detection.
Study III 
Design: A prospective single center pilot study including 30 patients with all stages 
of cervical cancer. 
Objectives: The aim was to explore the features of Strain elastography (SE) in 
patients with different disease stages and to evaluate the accuracy of SE for size 
measurements and tumour delineation in comparison to conventional US alone 
using histology after surgery as gold standard. 
Study IV 
Design: A single center diagnostic cohort study of 4 different groups of raters read-
ing US and MRI image material from 60 patients with all stages of cervical cancer
Objectives: To explore the inter-rater reproducibility of US and MRI raters with vary-
ing experience in a cohort of 60 patients with all stages of cervical cancer. Second-
ary aim was to evaluate accuracy in relation to experience and modality.
4.2.2.2 Methods (Study II-IV)
The patients were recruited at the first visit to Karolinska University Hospital after 
being diagnosed with invasive cervical cancer. As a routine at our institution, 
all the patients were clinically staged according to the FIGO’s 2009 diagnostic 
criteria for cervical cancer (42). Patients with all clinical stages were considered 
for participation, and those accepting were was asked to participate in a conven-
tional ultrasound examination and additional examinations with 3D, CEUS and SE. 
Not all patients accepted examination with all the different modalities, (Figure 
10), leading to different number of patients included in to each study. However, 
every participant (n=93) was examined with conventional ultrasonography as a 
baseline examination by one of 2 specialists, one with over 20 years experience 
(EE) in this field and another (KP) with 4 years’ experience on second-opinion 
ultrasonography. Cervical cancer US examination methodology and equipment 
has previously been described in our papers (165, 166) and chapter 4.2.1.3 in 
this thesis. All examinations were performed with TVS or TRS in combination 
with transabdominal ultrasound. Data was collected prospectively in case report 
form (CRF) on the day of ultrasound examination date, including information on 
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age and histology type according to biopsy. Subsequently clinical stage, date and 
outcome of surgery (type of surgical procedure and histological features) were 
filled out.
Magnetic resonance imaging (Used in Study IV)
According to routine at the institution all the patients included in study cohort II 
(n=93) were examined with MRI. At the time, imaging of the pelvis was performed 
with a phased array body coil using four different MR scanners. The images reviewed 
included high-resolution T2-weighted axial and sagittal images, oblique coronal 
images and oblique axial images (Figure 12) as well as T1-weighted axial images 
of the pelvis before, and after, administration of intravenous gadolinium-chelate 
contrast agent, either Gadopentetic acid (Magnevist 469 mg/mL, 0.2 mL/kg body-
weight, Bayer AB, Solna, Sweden) or Gadoteric acid (Dotarem 279.3 mg/mL, 0.2 
mL/kg bodyweight, Gothia Medical AB, Billdal, Sweden). Diffusion weighted images 
were excluded as they were not available for the whole study cohort. 
Histology (Study II-IV)
From cohort II (n=93), histology was available for surgically treated patients with 
early stage disease (n=52, 56%), (Table 5). According to routine at the department, 
a reference gynecology pathologist reviewed surgical specimens. Standard analysis 
for cervical cancer patients includes histological subtype, tumour dimension, depth 
of invasion to the cervical stromal, presence or absence of LVSI, parametrial inva-
sion as well as analysis of the lymph nodes. 
Contrast enhanced ultrasonography (Study II)
The CEUS examination of all the 70 participants, controls and patients, was per-
formed using Philips IU22 US system with a 3– 9MHz transducer. Through a periph-
eral vein the injected bolus of 2,5 ml contrast agent Sonovue® (Bracco International 
B.V., Amsterdam, The Netherlands) was followed by 5 ml saline solution. For opti-
mal orientation of the probe in relation to cervix, dual imaging was applied, splitting 
the screen for simultaneous CEUS and grayscale images. After injecting the contrast 
agent, a three-minute long video was recorded while holding the probe completely 
still. All the videos were analyzed at a separate occasion by two different examiners 
(EE and KP) several months after the closing of the study, to avoid bias. The readers 
were not blinded for case/control status of the image material. 
The semi-quantitative analyses were done with Philips software package QLAB® 
(release 10, Philips Ultrasound, Bothell, WA, USA). The software uses modeling to 
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Parametrial
invasion
Tumour
Disrupted
pericervical
fascia
Suspected
parametrial
invasion
Right side
Right side
a)
b)
Figure 12. MRI for the same patient as featured in Figure 6, a woman with stage IIB cervical cancer. 
Figure a is from oblique coronary axis with arrow pointing at parametrial invasion on the patients 
right side, b is from transverse axial plane showing disrupted pericervical fascia to the right side 
and to the left also suspected minimal invasion to the parametrium. Images provided by: Susanne 
Fridsten.
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draw a time-intensity curve (TIC) from a manually selected region of interest (ROI). 
A pre-fixed 5x5mm square was chosen to mark the ‘max intensity area’, while the 
ROI of the whole tumour/whole cervix was traced manually in different sizes, (Fig-
ure 13). Analyses were done on peak intensity of the contrast, time to peak, time 
to half wash out time and area under the curve (CEUAS-AUC) which reflects the 
intensity of the contrast during the specified time studied. Eleven patients and six 
controls were excluded from these analyses as their CEUS video had been saved in 
a format that could not be analyzed by the QLAB software.
For the qualitative analyses a simple subjective CEUS filling pattern classification 
system was invented where either a focal or a global filling (Figure 14) was seen 
in the uterine cervix. A wash out phenomenon, i.e. when a focal area looses the 
intensity prior to the surrounding was also observed.
Strain Elastography (Study III)
When the study was started, the plan was to use Voluson E8 ultrasound system 
with a 5-9 MHz transducer for the strain elastography examination. After having 
examined a couple of patients the image quality turned out very poor and fluctu-
ating, why decision was made to change to Philips IU22 US system with a 3– 9MHz 
transducer. Due to this, the results presented in this thesis refer only to patients 
Figure 13. TIC curve for the semi-quantitative analyses of the contrast kinetics. Green circle is 
region of interest (ROI) around the whole tumour; blue box is ROI for max intensity of contrast. 
Furthest down the x-axis is the time in seconds; y-axis is the intensity of contrast. The whole green 
shaded area is the CEUS AUC for intensity of contrast under the examination time. AIU = arbitrary 
intensity units
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examined with IU22. The SE examination was performed with TVS in conjunction to 
other US examinations. 
Placing light compression on the cervix, SE images and videos 15 to 30 seconds 
long were recorded. The SE images were retrospectively analyzed off-line using 
Philips software package QLAB®, (release 10, Philips Ultrasound, Bothell, WA, USA) 
by the author of this thesis who had not been involved in the real time examination. 
The tumour borders were first delineated on the grayscale image, then the same 
is done on the SE image to determine if SE facilitated tumour detection and delin-
eation. When tumour was identified on the SE images, size was measured in milli-
meters through cervical fundal diameter and anterioposterior diameter. Tumours 
were then classified by a five point elastography scoring system, using an accepted 
method that has been proposed for breast lesions by Itoh and colleagues 2006. The 
softest lesions are green receive a score 1, and the hardest lesions are blue with sur-
rounding tissue blue as well score 5 (146), Figure 15 reveals examples of tumours 
with different elasticity scores. 
Maximal strain ratio between the tumour lesion and the surrounding tissue was 
calculated in QLAB. Three patients with early stage disease were excluded from this 
analysis due to missing raw data. A pre-fixed 5 x 5 mm square was used, to mark the 
ROI and placed it at an area in the tumour and in the adjacent normal cervical stroma. 
Raters and reviewing of images (Study IV)
Two groups of raters were recruited for both modalities; one with experienced rat-
ers and another group of raters without previous experience of assessing patients 
with cervical cancer. See Table 6 for overview of the experience for each group of 
raters. The ultrasound experts were European Gynecologists (n=6) working as sec-
ond-opinion ultrasound experts. The group of less experienced ultrasound examin-
Figure 14. a) a focal filling pattern, arrow pointing at a tumour lesion, b) global pattern in a healthy 
cervical tissue.
Tumor
a) b)
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ers (n = 7), referred to as ‘US specialists’, consisted of Swedish subspecialized gyne-
cologists practicing at different hospitals in Stockholm. For the MRI reading, nine 
raters from Karolinska University Hospitals participated, 5 certified Radiologists and 
4 residents in radiology.
The US experts received a letter with a manual on how to execute the survey. An 
hour introduction lecture was held locally for the US specialists about ultrasound 
examination in patients with cervical cancer, giving examples on how to assess 
tumour visualization, 1/3 stromal- and parametrial invasion. Each of the US rater 
then received a flash hard drive and was asked to do off-line evaluation of the 
de-identified US images from 60 cases using their personal computers. MRI raters 
were introduced to basics of MRI reading for patients with cervical cancer during a 
two-hour lecture. The following two days they all reviewed the MRI images of the 
60 cases, using a PACS workstation at Karolinska University Hospital under surveil-
lance. All raters were informed that the cohort was a random mix including patients 
with all disease stages of cervical cancer.
Figure 15. Elasticity score in different patients, white circle in the image is marking the tumour. a) 
Elasticity score 2, different shades of green/red in the tumour b) Elasticity score 3, mosaicism of 
blue and green c) Elasticity score 4, blue in the center but green in the periphery d) Elasticity score 
5, tumour and surrounding tissue is blue 
a)
c)
b)
d)
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For each case, there were three clinical questions with binary answers, yes or 
no; 1) Is there a visible tumour; 2) does the tumour infiltrate > 1/3 of the cervi-
cal stroma; 3) is there parametrial invasion? Raters answered all the questions 
parallel online through a personalized link to an online survey (Survey Monkey®), 
see US Survey link and MRI Survey link. Agreement and accuracy was calculated 
for each group of raters on all the questions except that accuracy for parametrial 
invasion could not be calculated as none of the surgically treated patient turned 
out to have disease in the parametrium on final histology.
4.3 STATISTICAL ANALYSIS 
4.3.1 Study I-IV
A comparison was done of the mean (+/- SD) for normally distributed data and median 
(range) for non-parametric data. The chi-square test and Fisher´s exact test were used 
to compare categorical non-paired data as for color score, the Student´s t-test for 
normally distributed continuous data such as tumour diameter and the Mann-Whit-
ney U-test for non-parametric data such as 3D and CEUS parameters. ROC curves 
with AUC and 95% Confidence Intervals were used to study diagnostic performance 
Raters	(n) Years
US experts (6)  
Gynecologist 14,7 (5-24)
Second opinion US 10,5 (3-18)
Cervical cancer US 10,7 (3-18)
US specialists (7)  
Gynecologist 4,7 (2-8)
Second opinion US 1,3 (1-2)
Cervical cancer US 0
MRI experts (5)  
Radiologist 19,4 (10-30)
MRI 13,4 (4-25)
MRI pelvis 11,2 (1-25)
MRI residents (4)  
Resident radiology 4 (3-5)
MRI 0
MRI pelvis 0
(n) = number, years of experience are median (range)
Table 6. Experience of raters for both modalities.
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in relation to sensitivity and specificity of different US and 3D variables in study I and 
for different CEUS variables in study II.
For study III Bland-Altman plot with 95% limits of agreement were used to com-
pare size measurements from different modalities to histology. Comparing the 
index tests (SE and US) to the reference test (histology). 
For study II and IV Cohen’s Kappa (κ) was calculated for rater pairs and Fleiss’ 
kappa was calculated for group of multiple raters. In all cases where Kappa was 
calculated, agreement was interpreted as follows; Poor for κ = 0 – 0.2, fair for 
κ 0.21-0.40, moderate for κ 0.41-0.60, good for κ 0.61-0.80 and very good for κ 
0.81-1 according to Brennan and Silman (162). Sensitivity, specificity and accuracy 
for tumour seen, and stromal invasion > 1/3, were calculated for patients treated 
surgically, n = 31, using final histology as gold standard. Accuracy was calculated as 
a proportion of cases correctly classified divided by total case number. 
For all the studies a p-value < 0.05 was considered significant. All the analysis 
were done using SPSS (Statistical Package for Social Sciences) software version 
20-25 (IBM, Armonk, NY, USA) except the Bland-Altman plots in this thesis that are 
made in Graph Pad Prism (Version 6.0 for Windows, Graph Pad Software, La Jolla, 
CA, USA).
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5 RESULTS
5.1 STUDY I 
A total of 104 patients were included, 99 were operated with radical surgery includ-
ing hysterectomy or trachelectomy. Five patients were operated with lymph node 
dissection only as radical surgery was aborted due to findings of positive lymph 
nodes during surgery. Stage ≤ IB1 was found in 88/104 (85%) while 16/104 (15%) 
were assigned stage ≥ IB2. Squamous cell carcinoma was verified in 66/104 (60%), 
adenocarcinoma in 38/104 (37%) and mixed adenosquamous type in 4/104 (3%).
Patients with deep stromal invasion and lymph node metastases had bigger 
tumours in maximal diameter as measured with 2D US as well as larger volume as 
measured with 3D US (p=0.05), table 7. Tumours with deep stromal invasion and 
lymph node metastases had more often high color score, no differences were found 
on 3D vascular indices.
To predict deep stromal invasion subjective evaluation of images had higher sensi-
tivity and specificity than color score 4, 91% and 97% vs.79% and 52%, respectively, 
Table 8. Maximal tumour diameter had AUC of 0.83, sensitivity 91% and specificity 
61% at cut-off 20.5 mm, 3D volume had an AUC of 0.85, sensitivity 79% and speci-
ficity 83% at cut-off 9.1 mm3. Vascularity parameters VI, FI and VFI had no value to 
predict deep stromal invasion (Figure 16).
Table 7. 2D and 3D US parameters in tumours with and without deep stromal invasion (n=99) and 
lymph node metastases (n=104)
Deep	stromal	invasion Lymph	node	metastases
No Yes p-value* No Yes p-value*
2D
Max diameter 21.5 (10.1) 36.2 (11.9) < 0.001 29.8 (12.6) 35.5 (14.1) 0.05
Color score
Low-moderate 19 13 <0.001 28 5 0.065
High 17 50 48 23
3D
Volume 3.0 (0.1-29.5) 16.4 (0.7-94.2) < 0.001 9.5 (0.1-94.2) 15.7 (0.1-69.9) 0.03
VI 33.0 (7.6-74.7) 30.4 (2.5-68.5) 0.77 33.3 (2.5-74.6) 30.3 (7.4-61.3) 0.81
FI 38.8 (26.1-64.0) 38.6 (28.2-53.0) 0.45 39.8 (26.1-64.0) 38.0 (30.4-45.7) 0.52
VFI 13.2 (2.4-36.7) 11.6 (0.7-34.5) 0.61 13.2 (0.7-36.1) 12.3 (2.4-26.2) 0.76
Data are given as mean for diameter (+/-SD), number for color score and median (range) for 3D parameters. 
*Student t-test was used for diameter, Chi-square for color score and Mann-Whitney test for 3D parameters
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For detection of parametrial invasion subjective assessment had a sensitivity of 
100% (7/7) and specificity 95% (87/92). As only 7/99 patients had confirmed para-
metrial invasion on surgical specimen, no analysis was possible to explore the pre-
dictive value of different US parameters in this subgroup.
For detection of lymph node metastases, subjective assessment had a low sen-
sitivity and a high specificity, whereas prediction with color score 4 in the tumour 
tissue had a higher sensitivity than specificity (p<0.001), Table 8. All measurements 
from 2D or 3D parameters had poor diagnostic performance, see ROC curve (Figure 
17).
Maximal tumour size: AUC 0.83 
(95% CI 0.744-0.909, p<0.001)
3D volume: AUC 0.85 
(95% CI 0.78-0.94, p<0.001)
VI, FI and VFI: AUC 0.470-0.480
Figure 16. ROC curve for diagnostic performance of various 2D and 3D parameters to predict deep 
stromal invasion (n=99)
Maximal tumour size: AUC 0.620 
(CI 95% 0.490-0.748, p = 0.06)
3D volume: AUC 0.647 
(95%CI 0.522-0.772, p = 0.022)
VI, FI and VFI: AUC 0.469-0.493 
Figure 17. ROC curve for the performance of various 2D and 3D parameters to predict lymph node 
metastases (n=104)
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5.2 STUDY II 
The clinical characteristics of the patients are presented in Table 5. Median age 
of the patients was 43 (24-76) years. The clinical stages were the following, 35/49 
(71%) had ≤ Stage IB1 and 14/49 (29%) stages ≥ IB2. Squamous cell carcinoma was 
diagnosed in 30/49 (61%) and adenocarcinoma in 19/49 (39%). There were no dif-
ferences in the age (p =0.23) or menopause status (p=0.33) of the patients and 
controls.
Focal filling pattern was found in 3% (1/32) of the women with no tumour versus 
89% (34/38) of women with histologically detectable tumour, Table 9. Four patients 
with a residual tumour at histology had global distribution of contrast enhance-
ment. Three of those patients had clinical stage IB1 with very small tumours, the 
largest diameter measuring 6, 9 and 11 mm at histology, in total, eight patients had 
residual tumour size 1-20 mm. Further description of the CEUS pattern is presented 
in the paper from this study. 
In patients with early stage disease (n=31 surgically treated), a focal filling pattern 
had a sensitivity of 80% (16/20), specificity 91% (10/11), PPV 94% and NPV 71% for 
tumour detection as compared to sensitivity 85% (17/20), specificity 73% (8/11), 
Sensitivity Specificity PPV NPV p-value*
Deep stromal invasion
Subjective evaluation 91 (57/63)  97 (35/36)  98 (57/58)  85 (35/41) 0.125
Color score 4 79 (50/63) 53 (19/36) 75 (50/67) 53 (19/32)
Lymph node metastases
Subjective evaluation 43 (12/28) 96 (73/76) 80 (12/15) 82(73/89) <0.001
Color score 4 82 (23/28) 37 (28/76) 32 (23/71) 85 (28/33)
Table 8. Accuracy of Subjective evaluation and 2D Power Doppler color score to predict deep stro-
mal invasion (n=99) and lymph node metastases (n=104)
All numbers in % (n/N) *McNemar Chi-square to test significance between subjective evaluation and high 
color score
Controls Stage	≤1B1, Stage	≤	IB1, Stage	>	1B2
Filling	pattern (n=21) no	tumour	at	histology tumour	at	histology (n=14)
(n=11) (n=24)*
Global 21 10 3 1
Focal 0 1 21 13
Table 9. CEUS filling pattern in the whole study cohort (n=70), light blue box represents subjects 
without tumour, green box represents subjects with tumour, all stages.
*Including 4 patients who were not operated, 
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PPV 85% and NPV 73% of subjective assessment with conventional US alone, the 
difference was not statistically significant (p=1.00 for sensitivity and p=0.62 for 
specificity respectively). 
The inter-observer reproducibility in assessing the pattern of contrast distribution 
(focal versus global) was excellent (Kappa 0.91). The two examiners were in agree-
ment in the case of 30/32 focal and 37/38 global patterns.
The semi-quantitative analysis of contrast kinetics in healthy controls and patients 
with tumour is presented in Table 10. There was a statistically significant difference 
in the median peak intensity, area under the TIC curve (CEUS-AUC) and half wash-
out time between healthy cervical tissue and tumour lesions. No difference was 
found between the groups on time to peak of the contrast.
CEUS-AUC had excellent accuracy and peak intensity had moderate accuracy to 
distinguish tumour from healthy tissue, (Figure 18). 
Whole	cervix	or	tumour Controls	(n	=	15)
Cervical	cancer	with	 
tumour	(n	=	31*)
p-value†
Time to peak (sec) 18.6 (14.0–39.1) 19.8 (9.3–51.1) 0.98
Peak intensity (AIU) 5.4 (0.6–17.9) 18.2 (0.6–57.0) 0.002
Area under the curve (AIU x s) 205 (40–1737) 314820 (45–4888786) < 0.001
Half wash-out time (sec) 33.4 (16.1–112) 23.1 (9.3–112.7) 0.028
All numbers are presented as median (SD), † Mann Whitney t-test. *Seven patients without residual tumour 
at histology as well as eleven patients and six controls whose videos could not be analysed quantitatively 
were excluded.
Table 10. Semi-quantitative analysis of Contrast-enhanced ultrasound (CEUS) time-intensity curves 
from the whole cervix in controls and tumour lesions in patients with cervical cancer (n=46)
CEUS-AUC (AIU x sec): 
AUC 0.923 (95% CI 0.840-
1.00, p<0.001)
Peak intensity: 
AUC 0.778 (95% CI 0.646-
0.911, p = 0.002)
Figure 18. ROC curve for the diagnostic performance of CEUS specific parameters for tumour de-
tection, red line represent CEUS-AUC (Arbitrary Intensity Units x Seconds) of the contrast in whole 
tumour lesion, and blue line represents peak intensity. 
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5.3 STUDY III 
There were 30 patients included in the final analysis, 6 were excluded because they 
had no residual tumour at final histology, (flow chart of study cohort). Of the 20 
(66,7%) patients that had stage ≤ Ib1, 18 were surgically treated, (Table 5). 
Tumour delineation improved in 40% (8/20) of early stage and 70% (7/10) of the 
advanced stages by adding SE to conventional US alone. Size agreement between 
SE and histology (n=18) was excellent with no bias found (mean size difference -0.11 
mm, p= 0.657) by Bland Altman plot. The same was true for conventional US where 
the agreement was excellent as well, with no significant bias found (mean size dif-
ference 3.9 mm, p=0.488), (Figure 19).
An elasticity score of 4–5 was found in 45% (9/20) with early stage and 80% (8/10) 
with advanced disease (p = 0.068). The maximal strain-ratio was significantly (p < 
0.009) lower in early stages (1.9; SD ± 0.8), compared to advanced stages (3,1; SD 
±1.2).
5.4 STUDY IV
60 patients with all FIGO-stages were included for analysis by four different rater 
groups. The median time between US and surgery was 36 days (9-69), between MRI 
and surgery 42 days (4-71) and the median days between US and MRI was 5 days 
(0-45). 
For all parameters studied; tumour seen, >1/3 deep stromal invasion and para-
metrial invasion both US expert and specialist groups had a moderate inter-rater 
agreement with Fleiss’ kappa, (Table 11). The difference between the groups of 
experts versus specialists was not statistically significant for any of the questions 
Figure 19. Bland Altman plot with 95% limits of agreement for tumour size measured with conven-
tional US to the left where the pink line is the bias (mean difference). To the right strain elastography 
(SE) compared to histology after surgery (n=18), line for bias lies parallel to the reference line at zero.
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evaluated as seen by the overlapping CI. For MRI raters the agreement for the group 
of experts was good for all three questions with not statistical difference for Fleiss’ 
kappa compared to MRI residents except for evaluation of tumour seen where res-
idents had moderate agreement.
The sensitivity, specificity and accuracy for all the individual raters are presented 
in paper IV in this thesis. The range of accuracy for tumour visualization was as fol-
lows: US experts (68-74%), US specialists (61-77%), MRI experts (65-85%) and MRI 
residents (71-74%). For deep stromal invasion: US experts (58-74%), US specialists 
(48-74%), MRI experts (71-81%) and MRI residents (73-77%). As presented in Table 
12 there was no statistically significant difference on sensitivity, specificity or accu-
racy between the groups with different experience for either modality. 
Group	of	raters	 Fleiss	Kappa 95%	CI p-value*
Tumour seen yes/no
US experts 0.460 0.395-0.525 <0.001
US specialists 0.462 0.407-0.518 <0.001
MRI experts 0.696 0.616-0.776 <0.001
MRI residents 0.513 0.409-0.616 <0.001
Deep stromal invasion yes/no
US experts 0.445 0.380-0.511 <0.001
US specialists 0.525 0.470-0.581 <0.001
MRI experts 0.804 0.724-0.884 <0.001
MRI residents 0.709 0.606-0.812 <0.001
Parametrial invasion yes/no
US experts 0.573 0.507-0.638 <0.001
US specialists 0.442 0.387-0.497 <0.001
MRI experts 0.691 0.611-0.771 <0.001
MRI residents 0.711 0.607-0.814 <0.001
p-value for testing wether Fleiss’ Kappa  > 0
Table 11. The inter-rater agreement for diagnostic evaluation of study cohort (n=60) with Fleiss’ 
kappa for all rater groups.
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						Tumour	seen Deep	stromal	invasion
Raters yes   no Sensitivity Specificity Accuracy yes   no Sensitivity Specificity Accuracy
US experts 117   31 85% 35% 72% 61   24 64% 74% 69%
21   17 34   67
US specialists 127   27 79% 52% 72% 53   15 48% 86% 66%
34   29 58   91
p-value* 0.181 0.101 0.731 0.101 0.295 0.445
MRI experts 78   6 68% 85% 72% 48   5 60% 93% 76%
37   34 32   70
MRI residents 67   10 73% 69% 72% 46   11 72% 84% 73%
25   22 18   59
p-value* 0.459 0.90 0.797 0.06 0.06 0.905
*Mann-Whitney 
Table 12. The diagnostic accuracy of all rater groups (n=31)
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6 DISCUSSION
In this thesis three ultrasound modalities in addition to conventional US have been 
studied as well as inter-rater reproducibility of US and MRI raters with varying expe-
rience, in two cohorts of patients with cervical cancer. The main findings were:
Subjective assessment with conventional US had high accuracy to correctly 
diagnose patients with 2/3 deep stromal and parametrial invasion. Maximal 
tumour size measured with 2D US and tumour volume measured with 3D US was 
accurate to predict deep stromal invasion. All 3D PD vascular indices were useless 
for prediction of deep stromal invasion. To predict lymph node metastases, sub-
jective evaluation was the best method with a reasonable PPV and NPV at > 80%, 
whereas a color score of 4 had a high sensitivity but low specificity, resulting in a 
PPV of 32% and NPV of 85%. Size measurement by 2D US or 3D parameters did 
not add any additional information in prediction of lymph node metastases. 
Contrast kinetics were found different in cervical cancer tissue as compared to 
healthy cervical tissue with a higher peak intensity, higher CEUS-AUC as well as 
faster wash out time (p<0.05). The CEUS-AUC had very good performance to dis-
tinguish tumour tissue from healthy tissue. Focal contrast distribution was found in 
only 3% of the healthy controls and in cancer patients with no residual tumour after 
surgery versus in 89% of women with verified tumour. Tumour detection with the 
use of CEUS had in comparison to conventional ultrasound a higher specificity 91% 
vs. 73% at a similar sensitivity 85% vs. 80% although not statistically significant in 
this small series. The reproducibility for filling pattern was excellent between two 
readers (κ = 0.91).
Size agreement between SE and histology was excellent. An elasticity score of 4-5 
was found in 45% (9/20) with early stage and 80% (8/10) with advanced disease 
and max strain ratio was significantly lower in early stages compared to advanced 
stages. Tumour delineation improved in 40% of cases with early stage disease, in 
contrast to 70% of the cases with advanced stages with SE compared to conven-
tional US alone.
Reproducibility for US raters irrespective of experience was moderate for tumour 
visualization, > 1/3 deep stromal invasion and parametrial invasion. For MRI read-
ers the inter-rater reliability was good irrespective of experience except for tumour 
visualization where residents had a moderate agreement. This difference in agree-
ment was not reflected in accuracy as all rater groups had the same accuracy for 
tumour visualization and a not significant difference in evaluation of deep stromal 
invasion either, although the inter-rater range was wider for US raters. 
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6.1 THE RESULTS IN A CLINICAL CONTEXT
Study I and IV are more clinically applicable than study II and III which are pilot stud-
ies to explore a method that is previously not fully described or tested in patient 
settings. Taking into consideration the premises and limitation by a small study sam-
ple possible implications and clinical relevance will be discussed for all the studies. 
6.1.1 Tumour detection and size
When the project started, an important issue was the unknown reference value for 
the kinetics of contrast in healthy cervical tissue. As a result of this, healthy women 
were included as controls in study II, which would now be considered one of the 
main strengths of the study. An assumption was made that the best dosage and the 
expected kinetics of the contrast would be similar to other organs with single arte-
rial supply where recommended dosage is 2.4 ml as a bolus with intravenous injec-
tion (137, 167). A new classification system was invented with focal and global filling 
pattern. Although this system performed well with excellent inter-rater agreement 
and gave a higher specificity, it did not significantly increase the accuracy when 
compared to conventional US alone, possibly due to small sample size. 
It was disappointing that in three out of eight small tumours < 20 mm no focal 
contrast filling was noted and the tumours were classified as having a global fill-
ing pattern. The findings suggest that assessment with the filling pattern might not 
work optimally in the smallest tumours even if this study is too small to draw defin-
itive conclusion on this question. 
Further results were the promising performance of CEUS with semi-quantification 
especially CEUS-AUC (enhancement/sec), to distinguish between tumour tissue and 
healthy tissue. These findings are supported by another study on 60 patients with 
all stages of cervical carcinoma where 50% more intensity of contrast was found in 
tumours compared to the reference tissue (myometrium of the uterus) even a faster 
time to peak was noted (p <0.001). No differences in the contrast kinetics between dif-
ferent stages, tumour size or grade was found but a moderate correlation rho=0.624, 
p<0.001 between max contrast concentration and mean vascular density on histolog-
ical specimens (168). Direct comparison of the quantitative measurements is not pos-
sible as different equipment was used with different units, even if the contrast agent 
was the same. It is interesting though that they used lower dose of contrast agent (1 
ml vs. 2.5 ml) and still they had similar results. There is a certain risk for over-bloom-
ing of contrast related to higher dosage so according to these results our dose could 
be reduced. It is however doubtful that this would increase sensitivity of the filling 
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pattern for smaller tumours as they were classified with global filling with no signs of 
over-blooming pattern. Another important difference was that they used abdominal 
probes instead of the vaginal type applied in our and used myometrium as a reference 
standard. They consistently describe the same pattern as in study II with hyper-en-
hancement seen in the tumours in arterial phase and hypo-enhancement in the 
venous phase (wash out phenomena). Regardless of equipment or dosage of contrast 
there seems to be a window of 20-50 seconds after the injection of contrast agent 
where the contrast intensity peaks and allows evaluation the eventual tumour lesions 
before the effect has washed out again. Further validation of the contrast pattern of 
focal and global is motivated in a larger cohort as well as prospective trial to test differ-
ent cut-off values for contrast intensity to explore if further advances can be made in 
the diagnostics of the smallest tumours. 
Evaluation of tumour size with SE and grayscale showed good agreement with his-
tology in study III with no bias detected for either modality. The narrower limits of 
agreement for size difference with SE than for conventional US indicates that SE 
might improve the precision of size measurement for small tumours. These findings 
do confirm those from two previous studies, one small but very meticulously done 
study on 18 patients with mainly stage IB1 and from Testa’s study on 68 patients 
where no bias was found between histology and measurements with conventional 
US (105, 119). No studies have previously described the accuracy of SE for tumour 
measurements in this manner. To compare with previous findings on size mea-
surements with MRI the largest study published 2007 on 150 patients with stage ≤ 
IB1 showed a mean size difference between MRI and histology -0.9 mm with 95% 
limits of agreement between -12.6 to +13 mm (91). There a better agreement in 
tumours > 10 mm was noted, where the mean difference was 0.3 mm and the lim-
its of agreement were -7.5 to +7.9 mm. The limitations of that study were the low 
overall accuracy for tumour detection, and high number of misclassified patients 
(20/60) with residual tumour suspected on MRI where only inflammatory changes 
were seen on histology. Our preliminary results give the impression that the use 
of SE to measure size is accurate in early stage disease however not superior to 
conventional US solely or MRI. 
The accuracy of MRI raters (sensitivity 68%, specificity 85%) on tumour detec-
tion in study IV are almost exactly the same as in the previously mentioned MRI 
study from 2007 as well as what Epstein and colleagues reported for MRI on 182 
patients with early stage disease where sensitivity was 67% for tumour detection 
and specificity 89% with overall kappa = 0.52 between MRI and histology(1). On 
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the other hand, lower sensitivity 85% and specificity 37% for US experts was found 
when compared to Epstein’s study where the US raters had 90% sensitivity, 97% 
specificity. Indicating that tumour assessment in live settings with US seems to have 
higher accuracy when compared to off-line readings of image material, and gener-
ally lower inter-rater reliability than for MRI in these settings. 
6.1.2 Deep stromal invasion
What are the benefits of improving accuracy for detecting deep stromal invasion? 
The depth of stromal invasion has been linked to increased risk of recurrence and 
worse outcome in patients with early stage cervical cancer (78, 169, 170). In a large 
retrospective study aimed to find risk factors for parametrial invasion, data was 
prospectively collected for 842 cervical cancer patients with stage IA1-IB1 during an 
18-year period 1984-2002. The incidence of parametrial invasion was 6% overall, 
on the other hand for patients with tumour < 2 cm, no lymph node metastases and 
depth of invasion ≤ 10 mm the rate of parametrial invasion was only 0.6% (171). 
The authors concluded that there might be a certain low risk group of patient that is 
suitable for less radical surgery. Several small case series, of patients conservatively 
treated, report very good oncological outcome for patients with stage ≤ IB1 with 
low risk histology subtypes, tumour size < 2 cm and varying grade of deep stromal 
invasion and LVSI (75, 172-174). No prospective randomized trials are published 
but the ongoing SHAPE trial randomizes patients with tumours < 2 cm, stage IA2 or 
IB1 with stromal invasion ≤ 10 mm on cone biopsy or stromal invasion 50% or less 
on MRI to radical surgery or simple hysterectomy together with pelvic lymph node 
dissection. The primary results are awaited next year. This is especially important 
for younger patients with microscopic disease where retained fertility is a major 
issue. With highly accurate diagnostic imaging where remaining disease or depth 
of invasion in the cervical stroma could be excluded, some patients could be coun-
seled less radical surgery
According to the results in study I in addition to those previously presented from 
Testa and Epstein, Table 3 (1, 105) the subjective assessment is accurate and the 
best way to evaluate deep stromal invasion. Even if maximal tumour size with cut-
off 20.5 mm had a high sensitivity to predict deep stromal invasion, a size that is 
described in many studies as the limit for a low risk disease (76, 171, 175), it is 
unlikely that any US parameters will ever perform better as a predictive factor than 
the highly accurate subjective assessment.
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6.1.3 Parametrium 
Evaluating the parametrium or pericervical tissue is one of the main criteria when 
selecting patients for either primary surgical treatment or RCT. Clinical evaluation has 
been reported to have low sensitivity but high specificity and a moderate inter-ob-
server agreement for experienced clinicians for parametrial invasion (38, 41, 96). In 
study I, a high accuracy for evaluation of tumour in the parametrium was found with 
a negative predictive value of 100%. The high accuracy for conventional US evaluation 
of parametrial invasion in study I is in line with results from previously published stud-
ies (1, 104). Even MRI has previously been reported to have both high sensitivity and 
specificity for parametrial invasion as is discussed in the background, (Table 2) (96). 
With such high accuracy found for subjective assessment on conventional US in the 
settings of study I, any additional value of SE, CEUS or 3D is both unmotivated and 
impossible to study as the patients will be guided to primary RCT instead of surgery.
In study IV, a moderate agreement for both experienced and less experienced US 
raters was found for parametrial evaluation. The agreement for MRI raters was 
good irrespective of experience. For both modalities the agreement for less experi-
enced raters was better than the reported agreement (κ = 0.03) for less experienced 
raters had with clinical examination in another study (41) as well as the reliability 
found between 4 raters for parametrial invasion (κ = 0.11) in the ACRIN/GOG study 
(156). One reason for the difference between the agreement of MRI raters in this 
study compared to the ACRIN/GOG study is the high proportion of patients with 
advanced disease, much smaller number of patients included and improved image 
quality in study IV. One explanation for the lower reliability found for the US raters 
is the lacking perception of the organs under examination, an important part of 
the life examination. As a conclusion, both MRI and US will increase the diagnostic 
accuracy for the evaluation of tumour in the parametrium when compared to clin-
ical examination alone with generally higher agreement for MRI raters in off-line 
settings.
6.1.4 Lymph nodes
To date available diagnostic imaging modalities lack accuracy to detect metastases 
in the lymph nodes especially in low volume disease. One of the strengths of study 
I is the relatively high number of lymph node metastases in patients treated with 
surgery that made it possible with adequate sample size to evaluate the 3D US. 
Subjective assessment of lymph node metastases had a reasonable PPV and NPV 
(around 80%) in study I, however, a low sensitivity restricting the method. As low 
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sensitivity was expected, the aim was to study more specifically if 2D or 3D PD 
vascular indices would have some additional value to predict which patients would 
have lymph node metastases. Color score 4 was found in 23/28 patients with lymph 
node metastases with 2D PD and in 48/76 that did not have metastases, giving a 
very low PPV. So even if the tumours were generally well vascularized, irrespective 
of the findings of positive lymph nodes or not, the 3D vascularity indices turned out 
to be non informative for prediction more advanced disease. These findings are in 
agreement with two other studies showing no correlation between 3D PD indexes 
and lymph node metastases (126, 127). In these studies, the same US system was 
used and 4D view was used for analysis so the results are comparable. Our results 
are further confirmed by Alcazars findings on the uselessness of 3D-PD indices to 
predict recurrence after RCT in patients with locally advanced disease (130). Sum-
marizing the published evidence, there is nothing to support the value of 3D-PD 
indices as a predictor for finding lymph node metastases or for monitoring thera-
peutic response in patients with cervical cancer. 
It is interesting to put the results from study I in context with the results of study II. 
An abundant vascularity/high color score in almost all cervical tumours using Power 
Doppler in study I is in agreement with previous studies on cervical tumours (116, 
176). As 3D PD vascularity indices were non-informative, another interesting aspect 
is the quantification of contrast kinetics as seen in study II as a surrogate for neo-
vascularization. Zheng and colleagues found that the micro vessel density of small 
blood vessels in cervical tumours correlates to intensity of contrast (168). Higher 
micro vessel density in cervical cancer has been linked to worse survival for patient 
with node negative disease stage IB1 (177), moreover, the most recent addition to 
the therapy arsenal for patients with advanced and recurrent cervical cancer is an 
anti-angiogenic agent (178). This makes CEUS more interesting as a possible diag-
nostic method in the future for clinical applications such as examining lymph nodes, 
association to prognostic factors or for monitoring specific therapy response. 
Metastases in the lymph nodes and parametrial invasion are poor prognostic fac-
tors and these findings should be included in the evaluation when patients are tri-
aged for appropriate treatment. The main goal has been to avoid dual treatment 
with both surgery and radiation in patients with early stage disease as this increases 
morbidity without improving survival (80). The future role of predicting lymph node 
metastasis using imaging in patients with early stage disease is uncertain, as the 
question remains unanswered if radical lymph node dissection in patients with 
early stage cervical cancer is only diagnostic and not therapeutic. Some evidence 
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supports radical lymph node dissection as a therapeutic procedure. According to 
Höckel and colleagues, who have presented survival data (96% 5 years OS) supe-
rior to other studies for surgically treated patients with cervical cancer (stage ≤ IIB) 
without postoperative adjuvant treatment, the radical lymph node dissection is the 
most important aspect of the surgical treatment and not the radical hysterectomy. 
This is included in a surgical concept called total mesometrial resection (TMMR) 
where surgical dissection follows embryological development with different ana-
tomical definition (179, 180). This approach is appealing especially in the light of 
recently published evidence regarding worse survival with MIS, still, Höckel´s results 
are yet to be reproduced. Until further research is published, SNB has to be consid-
ered the best available diagnostic complement to insufficient diagnostic imaging on 
the lymph nodes in patients with early stage cervical cancer. 
6.1.5 Locally advanced stages
In study III tumours in patients with advanced stages were more easily demarcated, 
had higher strain ratio and a tendency for a higher elasticity score even if it was not 
statistically significant compared to early stages, probably due to a small patient 
cohort. The max strain ratio found in tumours both early (1.87) and advanced (3.06) 
was lower than in previously published studies where a strain ratio of 4.5 was sug-
gested as a cut-off between benign and malignant cervical tissue (152, 181). These 
difference are explained by different study populations as patients with benign con-
ditions such as cervical fibroma and dysplasia were included in the other studies, 
another reference tissue used for the calculation of strain ratio (parametrium) and 
last but not least different US equipment was applied both for examination and 
software for the analysis. 
It is not obvious how the quantification of strain ratio can be applied in the diag-
nostic workup of cervical cancer patients for the time being. It should definitely 
not be used in the differential diagnosis between benign or malignant lesions as 
suggested by previously published studies, as tissue biopsy must be the gold stan-
dard to rule out cancer. It is not applicable either to figure out if patients have an 
advanced tumour or not, as more detailed morphological analysis on the dissem-
ination is needed before treatment is started. The strain ratio could on the other 
hand be further tested to evaluate response to given RCT as has been suggested 
in another small study on patients with advanced stage disease (153). One study 
has reported higher accuracy for parametrial examination by adding SE to TVS as 
compared to TVS alone, however in that study both sensitivity and specificity of 
TVS alone were much worse than in previous larger multicenter study (182) and 
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compared to our findings in study I. As a result, no firm conclusion can be drawn on 
the role of SE in the evaluation of patients with cervical cancer for the time being 
neither from our study or other published studies on the subject. 
6.1.6 Reproducibility
What is measured by inter-rater reproducibility and what affects the agreement 
between different raters? In study IV, two questions were interesting; the first one 
was if different modalities are comparable for the evaluation of patients with cervi-
cal carcinoma, and secondly if experience affects how well raters agree. Even if the 
results have been discussed in clinical context, the three important variables that 
can have affected the outcome of this study deserve more attention; the cohort 
of patients being examined, the raters doing the evaluation and the method used. 
The prevalence of the condition being examined is important as rare conditions 
are likely to give lower agreement between raters (183). This would not be consid-
ered the case in our study, as it was a mixed cohort with all disease stages represen-
tative for our institution. The time between the US and MRI was only 5 days so the 
risk for differences in the disease stage are small. 
There is certain heterogeneity within the different rater groups and the lower 
agreement for US raters could partly be a reflection of this. The most important is 
the different number of raters for each modality. The MRI raters were fewer, came 
from the same hospital and did the image readings in settings similar to the usual 
clinical ones. The US raters on the other hand were from different institutions in 
different countries, reading the images in settings unlike the clinical ones as unfor-
tunately, reproducibility studies in live settings with multiple raters for US are not 
feasible. 
Finally, the methods have intrinsic different characteristics and are expected to 
have different sensitivity and specificity as has been discussed previously. A bias is 
most likely introduced by using off-line settings for a method that is strongly depen-
dent on the live examination settings as is the case for US. The results of equal 
agreement between experienced and less experienced raters on both modalities 
support this. 
The main goal of calculating accuracy for the raters in the study was to put the 
inter-rater agreement in better context and to see if the agreement really mirrors 
the accuracy, furthermore, to examine if the accuracy in the off-line settings is 
comparable to live settings for the US. As previously discussed the accuracy was 
generally lower for US raters than seen in previous accuracy studies for ultrasound 
for both question. As a conclusion, evaluation of US images is most accurate in the 
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hands of the performing examiner who should evaluate the images in context to 
the live settings, as the method is less reliable and less accurate in off-line settings. 
6.2 METHODOLOGICAL CONSIDERATIONS
One of the main challenges of this thesis was the collection and analysis of the CEUS 
and SE material. Even if research was done prior to starting the studies, unexpected 
problems were first revealed in real life settings. As previously described there 
were technical problems in the beginning when using SE leading to lost study mate-
rial and as a result of this the final study population became smaller than initially 
planed. The same was true for the CEUS as the software used for the analysis can 
only read raw files a substantial part of the study material could not be included in 
the semi-quantitative analysis as the files had been recorded in the wrong format. 
Further challenge is holding the probe still for a long time during the CEUS examina-
tion. To diminish the risk of error due to movement of the probe in the semi-quanti-
tative analysis, the patients were examined in only in one plane. This is a challenge 
for the examiner rather than the patient and a restriction of the method. 
The sample sizes in study II and III are small and it creates a low statistical power 
and generalizability. When small cohorts are divided into subgroups a risk of statis-
tical error and random findings/associations is created. As the cohorts in the thesis 
consisted of a majority of cases with early stage disease, no definitive conclusions 
can be drawn on the more advanced stages. 
6.2.1 Selection bias 
When patients are not recruited to the study randomly or consecutively or they 
do not represent the intended spectrum of target disease a selection bias is intro-
duced. All the patients to study cohort II are recruited from Karolinska University 
Hospital at the time of diagnosis. During the 5 years of inclusion to our studies, 
approximately 20% of the patients diagnosed with cervical cancer in the region par-
ticipated. The rate was fastest for inclusion between 2012 midyear until late 2014 
but inclusion in to the study was extended to 2015 because of lacking material for 
the CEUS analysis. To avoid selection bias a systematic invitation to the study was 
included in the first visit to the Hospital. It is impossible to exclude that for some 
reasons some patients were not invited to participate as no registration was held 
on how many were screened for inclusion. The same is true for study I, where each 
center was responsible for recruiting patients, no registration is available for how 
many were screened. A certain spectrum bias can be found in the first study as 
more advanced stages are included for surgical treatment than would be accepted 
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here in Sweden and other Nordic countries. When comparing our study cohort II to 
the overall population of patients in Sweden with cervical cancer the age is similar 
as well as the proportion of patients with different histological subtypes and stages. 
6.2.2 Information bias 
Is a bias created when the results of the index test (US examinations) are interpreted 
with awareness of the results of the reference test. It can also cause information 
bias if the readers/raters get more or less information than would be available in 
clinical practice. There is risk for this type of bias in our studies because the raters of 
the CEUS examinations were not blinded to the control/patient status of the study 
participants. The raters were not blinded either by the clinical stage of patients 
in study II or III that could have influenced how patients were subjectively classi-
fied into global/focal pattern or if SE was subjectively evaluated as useful or not. In 
study IV, the raters had no information on the clinical stage, histological results or 
the primary results of the index test, as a result the accuracy could be lower than 
expected.
6.2.3 Verification bias
When a nonrandom set of patients do not go through reference test or when a 
subset of patients are verified or selected by a third reference test (MRI in this 
case). This is an actual problem in our settings. Even though the patients are clin-
ically staged according to FIGO, the actual selection for surgical treatment is in 
many cases based up on the MRI findings. This has been verified in other studies 
(92, 157). Especially would tumour size, parametrial invasion or strongly suspected 
lymph node metastases direct the patients to primary RCT and no reference test 
results are then available for comparison to the index test. This creates a bias as the 
index test is then evaluated on a preselected group that consists of the cases clas-
sified by the MRI examination. This could lead to underestimation of the accuracy 
of the index test. 
6.2.4 Classification bias
The time between US examination and operation in the patients with early stage 
disease can have created a classification bias. The risk that the disease has changed 
between the index test and reference test can not be eliminated as there was over 
one month between the two in study cohort II. That would potentially underesti-
mate the ability of the index test to correctly classify the disease. By asking ques-
tions with binary answers like was the case in study IV, the diagnostic performance 
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of a rater is probably not truly revealed as the answers in clinical settings are rarely 
definite. This can underestimate or overestimate the true accuracy.
Another type of classification bias can occur when the reference test does not 
measure what it should measure. As some factors of the histology examination are 
subjectively evaluated such as the deep stromal invasion such bias is possible. 
6.2.5 Validity
6.2.5.1 Internal validity
All the US modalities studied in this thesis are additional methods where conven-
tional grayscale with Power Doppler is a baseline examination. The methods are 
strongly interwoven and the impact of the basic 2D US examination when subjec-
tively evaluating the additional usefulness of 3D, CEUS or SE is inseparable. As a 
result of this, the true accuracy i.e. for filling pattern with CEUS is impossible to 
evaluate separately. As published in the paper from study II there were two raters 
doing the pattern recognition separately with an overall agreement of 91% that 
strengthens the validity of the classification. By doing both the pattern recognition 
and the quantitative measurement further strengthens the findings. Even though 
the calculations/quantifications from software programs such as 4D view and QLAB 
are estimates it is still an endeavor to get closer to true value of the method. Other 
concern is the histopathological evaluation that was not performed by a study spe-
cific pathologist. There is inevitable inter-observer variation imbedded in the test 
used as reference test that weakens the internal validity. 
6.2.5.2 External validity
There are limitations to the external validity due to the technical issues described 
with CEUS and SE as well as the bias included in the quantification both by the 
software and by the examiner. There is a learning curve when these methods are 
applied and errors occur as a result of this. The methods need further improve-
ment, especially the software for analysis and validation is essential with further 
prospective studies before clinical application is actual. Further limitation is the 
small number of patients for study II and III especially patients with advanced dis-
ease. For early stage disease the external validity is better as the number of patients 
is higher and the results are validated with histological results. For the 3D examina-
tion, the external validity is good as we have reproduced previous study results and 
the method as such is much more extensively studied and developed compared to 
CEUS and SE. The results are applicable to settings with same equipment used and 
the reproducibility for the rater groups applies to off-line settings. 
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The two cohorts are different. In study I there is a certain heterogeneity as more 
advanced stages were included from European centers. That led to high incidence 
of lymph node metastases, higher than expected in our settings at Karolinska Uni-
versity Hospital and other Nordic centers, this is a concern for the external valid-
ity as most centers at least in the Nordic countries do not surgically treat patients 
with tumour size > 4 cm or with suspect parametrial invasion. It can also affect 
the predictive value of a diagnostic method when the prevalence of a condition is 
increased or decreased. However, in this case it provided the chance to evaluate the 
sensitivity and specificity of the conventional 2D US in a relatively large prospective 
cohort both for the evaluation of deep stromal invasion, parametrial invasion and 
for the lymph nodes and therefore has to be considered as one of the strengths of 
the study.
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7 CONCLUSION
Assessment of deep stromal and parametrial invasion with conventional US is accu-
rate in live settings and is done best by subjective assessment. 
Three-dimensional ultrasonography does not improve the evaluation of patients 
with early stage cervical cancer, neither 3D-PD indices nor volume measurements 
add any value to predict deep stromal invasion or lymph node metastases. 
The addition of contrast-enhanced ultrasonography may increase the accuracy of 
tumour detection both by pattern recognition and by quantitative measures. 
Strain Elastography has high accuracy for measuring tumour size in patients with 
early stage disease and appears to facilitate tumour outlining in patients with locally 
advanced disease compared to conventional US alone.
In off-line settings, inter-rater reliability for local assessment of cervical cancer 
patients by US images is moderate while it is moderate-good for MRI raters, where 
the experience of the raters does not affect the outcome for either modality. 
As confirmed in this thesis, the conventional US is an accurate method for tumour 
assessment, where additional modalities must be outstanding to improve the over-
all diagnostic accuracy. Only marginal effect was measureable by adding CEUS and 
SE to the conventional US in the studies and as a result, no clinical application could 
be established. As a conclusion, current evidence does not support the routine use 
of 3D US, CEUS nor SE as an addition to conventional US for the workup of patients 
with cervical carcinoma. 
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8 FUTURE PERSPECTIVES
Further improvements of the SE and CEUS technique are desirable to facilitate the 
application in clinical settings. If the methods become more user friendly, further 
studies could be motivated with focus on the potential benefit of CEUS in patients 
with early stage disease. In a prospective validation study the cut-off values for 
CEUS-AUC suggested in our pilot study could be tested and the histological charac-
teristics of tumours in relation to CEUS kinetics as well. Another possibility would 
be to study if CEUS is applicable for lymph node assessment in patients with normal 
sized lymph nodes as the distinct focus of contrast is noted in cancer lesions. 
The future challenge will be to perform high quality research on a relatively uncom-
mon disease, where the available diagnostic methods have already reach an accept-
able level of accuracy for some of the most relevant clinical questions. How is it 
possible to come one step further, for instance to fine tune the diagnostics of the 
lymph nodes or find the microscopic cervical tumour with imaging? The solution 
is unlikely to be discovered with small, single center studies, and resources should 
instead be put into well-organized, multi-center studies with adequate sample size 
to possibly make progress towards better results in the management of this import-
ant patient group. 
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